JANEL CORP - Quarter Report: 2019 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2019
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from __ to __
Commission file number: 333-60608
JANEL CORPORATION
(Exact name of registrant as specified in its charter)
Nevada
|
86-1005291
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
303 Merrick Road - Suite 400
|
||
Lynbrook, New York
|
11563
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: (516) 256-8143
Former name, former address and former fiscal year if changed from last report: N/A
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading symbols(s)
|
Name of each exchange on which registered
|
||
None
|
None
|
None
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☐ No ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☐ No ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☒
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes ☐ No ☒
The number of shares of Common Stock outstanding as of November 22, 2019 was 847,412.
JANEL CORPORATION
QUARTERLY REPORT ON FORM 10-Q
For Quarterly Period Ended March 31, 2019
Page
|
|||
Part I - Financial Information
|
|||
Item 1.
|
Financial Statements:
|
||
3
|
|||
4
|
|||
5
|
|||
6
|
|||
7
|
|||
Item 2.
|
26
|
||
Item 4.
|
38
|
||
Part II - Other Information
|
|||
Item 1.
|
40 | ||
Item 1A.
|
40
|
||
Item 2.
|
40 | ||
Item 6.
|
40
|
||
41
|
PART I - FINANCIAL INFORMATION
JANEL CORPORATION AND SUBSIDIARIES
(in thousands, except share and per share data)
March 31,
2019
(Unaudited)
|
September 30,
2018
|
|||||||
ASSETS
|
||||||||
Current Assets:
|
||||||||
Cash
|
$
|
1,381
|
$
|
585
|
||||
Accounts receivable, net of allowance for doubtful accounts
|
21,881
|
19,726
|
||||||
Inventory
|
2,392
|
2,391
|
||||||
Prepaid expenses and other current assets
|
502
|
354
|
||||||
Total current assets
|
26,156
|
23,056
|
||||||
Property and Equipment, net
|
3,903
|
3,787
|
||||||
Other Assets:
|
||||||||
Intangible assets, net
|
12,958
|
12,347
|
||||||
Goodwill
|
12,061
|
11,458
|
||||||
Security deposits and other long term assets
|
270
|
263
|
||||||
Total other assets
|
25,289
|
24,068
|
||||||
Total assets
|
$
|
55,348
|
$
|
50,911
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current Liabilities:
|
||||||||
Line of credit
|
$
|
11,970
|
$
|
9,730
|
||||
Accounts payable - trade
|
16,856
|
16,798
|
||||||
Accrued expenses and other current liabilities
|
2,939
|
1,748
|
||||||
Dividends payable
|
740
|
470
|
||||||
Current portion of long-term debt
|
1,145
|
897
|
||||||
Total current liabilities
|
33,650
|
29,643
|
||||||
Other Liabilities:
|
||||||||
Long-term debt
|
3,236
|
3,831
|
||||||
Subordinated promissory notes
|
620
|
344
|
||||||
Mandatorily redeemable non-controlling interest
|
681
|
681
|
||||||
Deferred income taxes
|
1,402
|
1,131
|
||||||
Other liabilities
|
310
|
254
|
||||||
Total other liabilities
|
6,249
|
6,241
|
||||||
Total liabilities
|
39,899
|
35,884
|
||||||
Stockholders' Equity:
|
||||||||
Preferred Stock, $0.001 par value; 100,000 shares authorized
|
||||||||
Series B 5,700 shares authorized and 1,271 shares issued and outstanding
|
-
|
-
|
||||||
Series C 20,000 shares authorized and 20,000 shares issued and outstanding at March 31, 2019 and September 30, 2018, liquidation value of $12,240 and $11,966 at March 31, 2019 and September 30,
2018, respectively
|
-
|
-
|
||||||
Common stock, $0.001 par value; 4,500,000 shares authorized, 839,451 issued and 819,451 outstanding as of March 31, 2019 and 837,951 issued and 817,951 outstanding as of September 30, 2018
|
1
|
1
|
||||||
Paid-in capital
|
15,543
|
15,872
|
||||||
Treasury stock, at cost, 20,000 shares
|
(240
|
)
|
(240
|
)
|
||||
Accumulated earnings (deficit)
|
145
|
(606
|
)
|
|||||
Total stockholders' equity
|
15,449
|
15,027
|
||||||
Total liabilities and stockholders' equity
|
$
|
55,348
|
$
|
50,911
|
The accompanying notes are an integral part of these consolidated financial statements.
JANEL CORPORATION AND SUBSIDIARIES
(in thousands, except share and per share data)
(Unaudited)
Three Months Ended
March 31,
|
Six Months Ended
March 31,
|
|||||||||||||||
2019
|
2018
|
2019
|
2018
|
|||||||||||||
Revenue
|
$
|
20,969
|
$
|
15,870
|
$
|
43,296
|
$
|
30,650
|
||||||||
Forwarding expenses and cost of revenues
|
14,599
|
11,029
|
30,439
|
21,219
|
||||||||||||
Gross profit
|
6,370
|
4,841
|
12,857
|
9,431
|
||||||||||||
Cost and Expenses:
|
||||||||||||||||
Selling, general and administrative
|
5,692
|
4,781
|
11,081
|
8,880
|
||||||||||||
Amortization of intangible assets
|
236
|
201
|
444
|
394
|
||||||||||||
Total Costs and Expenses
|
5,928
|
4,982
|
11,525
|
9,274
|
||||||||||||
Income (Loss) from Operations
|
442
|
(141
|
)
|
1,332
|
157
|
|||||||||||
Other Items:
|
||||||||||||||||
Interest expense net of interest income
|
(198
|
)
|
(117
|
)
|
(360
|
)
|
(234
|
)
|
||||||||
Income (Loss) Before Income Taxes
|
244
|
(258
|
)
|
972
|
(77
|
)
|
||||||||||
Income tax (expense) benefit
|
(69
|
)
|
41
|
(253
|
)
|
40
|
||||||||||
Net Income (Loss)
|
175
|
(217
|
)
|
719
|
(37
|
)
|
||||||||||
Preferred stock dividends
|
(148
|
)
|
(91
|
)
|
(270
|
)
|
(197
|
)
|
||||||||
Gain on extinguishment of Preferred Stock Series C dividends
|
-
|
-
|
-
|
1,312
|
||||||||||||
Net Income (Loss) Available to Common Stockholders
|
$
|
27
|
$
|
(308
|
)
|
$
|
449
|
$
|
1,078
|
|||||||
Net Income per share
|
||||||||||||||||
Basic
|
$
|
0.21
|
$
|
(0.38
|
)
|
$
|
0.85
|
$
|
(0.06
|
)
|
||||||
Diluted
|
$
|
0.18
|
$
|
(0.38
|
)
|
$
|
0.77
|
$
|
(0.06
|
)
|
||||||
Net income (loss) per share attributable to common stockholders:
|
||||||||||||||||
Basic
|
$
|
0.04
|
$
|
(0.54
|
)
|
$
|
0.53
|
$
|
1.91
|
|||||||
Diluted
|
$
|
0.03
|
$
|
(0.54
|
)
|
$
|
0.48
|
$
|
1.91
|
|||||||
Weighted average number of shares outstanding:
|
||||||||||||||||
Basic
|
847,784
|
568,974
|
847,621
|
565,629
|
||||||||||||
Diluted
|
931,960
|
568,974
|
934,137
|
565,629
|
The accompanying notes are an integral part of these consolidated financial statements.
JANEL CORPORATION AND SUBSIDIARIES
(in thousands, except share and per share data)
(Unaudited)
PREFERRED STOCK
|
COMMON STOCK
|
PAID-IN
CAPITAL
|
TREASURY STOCK
|
RETAINED
EARNINGS
|
TOTAL
EQUITY
|
|||||||||||||||||||||||||||||||
SHARES
|
$
|
SHARES
|
|
$ | $ |
SHARES
|
$ | $ | $ | |||||||||||||||||||||||||||
Balance - September 30, 2018
|
21,271
|
$
|
-
|
837,951
|
$
|
1
|
$
|
15,872
|
20,000
|
$
|
(240
|
)
|
$
|
(606
|
)
|
$
|
15,027
|
|||||||||||||||||||
Net Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
719
|
719
|
|||||||||||||||||||||||||||
Cumulative effect of change in accounting principle
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
32
|
32
|
|||||||||||||||||||||||||||
Dividends to preferred stockholders
|
-
|
-
|
-
|
-
|
(270
|
)
|
-
|
-
|
-
|
(270
|
)
|
|||||||||||||||||||||||||
Vested restricted stock unissued
|
-
|
-
|
-
|
-
|
(236
|
)
|
-
|
-
|
-
|
(236
|
)
|
|||||||||||||||||||||||||
Stock based compensation
|
-
|
-
|
-
|
-
|
172
|
-
|
-
|
-
|
172
|
|||||||||||||||||||||||||||
Stock option exercise
|
-
|
-
|
1,500
|
-
|
5
|
-
|
-
|
-
|
5
|
|||||||||||||||||||||||||||
Balance - March 31, 2019
|
21,271
|
$
|
-
|
839,451
|
$
|
1
|
$
|
15,543
|
20,000
|
$
|
(240
|
)
|
$
|
145
|
$
|
15,449
|
PREFERRED STOCK
|
COMMON STOCK
|
PAID-IN CAPITAL
|
TREASURY STOCK
|
RETAINED EARNINGS
|
TOTAL EQUITY
|
|||||||||||||||||||||||||||||||
SHARES
|
|
$ |
SHARES
|
$ | $ |
SHARES
|
$ | $ | $ | |||||||||||||||||||||||||||
Balance - September 30, 2017
|
35,476
|
$
|
-
|
573,951
|
$
|
1
|
$
|
12,312
|
20,000
|
$
|
(240
|
)
|
$
|
(854
|
)
|
$
|
11,219
|
|||||||||||||||||||
Net Income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(37
|
)
|
(37
|
)
|
|||||||||||||||||||||||||
Issuance of Series C Preferred Stock
|
3,000
|
-
|
-
|
-
|
1,500
|
-
|
-
|
-
|
1,500
|
|||||||||||||||||||||||||||
Dividends to preferred stockholders
|
-
|
-
|
-
|
-
|
(197
|
)
|
-
|
-
|
-
|
(197
|
)
|
|||||||||||||||||||||||||
Stock option exercise
|
-
|
-
|
14,000
|
-
|
45
|
-
|
-
|
-
|
45
|
|||||||||||||||||||||||||||
Stock based compensation
|
-
|
-
|
-
|
-
|
296
|
-
|
-
|
-
|
296
|
|||||||||||||||||||||||||||
Balance - March 31, 2018
|
38,476
|
$
|
-
|
587,951
|
$
|
1
|
$
|
13,956
|
20,000
|
$
|
(240
|
)
|
$
|
(891
|
)
|
$
|
12,826
|
The accompanying notes are an integral part of these consolidated financial statements.
JANEL CORPORATION AND SUBSIDIARIES
(in thousands)
(Unaudited)
Six Months Ended
March 31,
|
||||||||
2019
|
2018
|
|||||||
Cash Flows From Operating Activities:
|
||||||||
Net income (loss)
|
$
|
719
|
$
|
(37
|
)
|
|||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Provision for uncollectible accounts
|
330
|
(7
|
)
|
|||||
Depreciation
|
152
|
51
|
||||||
Deferred income tax
|
302
|
(40
|
)
|
|||||
Amortization of intangible assets
|
444
|
394
|
||||||
Amortization of acquired inventory valuation
|
129
|
-
|
||||||
Amortization of loan costs
|
5
|
5
|
||||||
Stock based compensation
|
236
|
416
|
||||||
Changes in operating assets and liabilities, net of effects of acquisitions:
|
||||||||
Accounts receivable
|
(1,002
|
)
|
1,355
|
|||||
Inventory
|
(131
|
)
|
19
|
|||||
Prepaid expenses and other current assets
|
(134
|
)
|
(91
|
)
|
||||
Security deposits and other long term assets
|
(5
|
)
|
(20
|
)
|
||||
Accounts payable and accrued expenses
|
171
|
(841
|
)
|
|||||
Other liabilities
|
56
|
-
|
||||||
Net cash provided by operating activities
|
1,272
|
1,204
|
||||||
Cash Flows From Investing Activities:
|
||||||||
Acquisition of property and equipment, net of $13 in disposals
|
(253
|
)
|
(38
|
)
|
||||
Acquisitions
|
(1,935
|
)
|
(2,321
|
)
|
||||
Net cash used in investing activities
|
(2,188
|
)
|
(2,359
|
)
|
||||
Cash Flows From Financing Activities:
|
||||||||
Dividends Paid
|
-
|
(7
|
)
|
|||||
Repayments of term loan
|
(491
|
)
|
(629
|
)
|
||||
Proceeds from sale of Series C Preferred Stock
|
-
|
1,500
|
||||||
Proceeds from stock option exercise
|
5
|
45
|
||||||
Line of credit, proceeds, net
|
2,234
|
504
|
||||||
Repayment of notes payable - related party
|
(36
|
)
|
(500
|
)
|
||||
Net cash provided by in financing activities
|
1,712
|
913
|
||||||
Net increase (decrease) in cash
|
796
|
(242
|
)
|
|||||
Cash at beginning of the period
|
585
|
988
|
||||||
Cash at end of period
|
$
|
1,381
|
$
|
746
|
||||
Supplemental Disclosure of Cash Flow Information:
|
||||||||
Cash paid during the period for:
|
||||||||
Interest
|
$
|
360
|
$
|
229
|
||||
Income taxes
|
$
|
81
|
$
|
62
|
||||
Non-cash investing activities:
|
||||||||
Contingent earn-out acquisition
|
$
|
50
|
$
|
498
|
||||
Subordinated Promissory notes of Honor
|
$
|
456
|
$
|
-
|
||||
Non-cash financing activities:
|
||||||||
Dividends declared to preferred stockholders
|
$
|
270
|
$
|
190
|
||||
Vested restricted stock unissued
|
$
|
236
|
$
|
-
|
The accompanying notes are an integral part of these consolidated financial statements.
JANEL CORPORATION AND SUBSIDIARIES
(in thousands, except share and per share data)
1. |
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
|
The accompanying interim unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of Article 8 of Regulation S-X and the instructions to Form 10-Q of the
Securities and Exchange Commission. As a result, certain information and footnote disclosures normally included in audited financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. Janel
Corporation (the “Company" or "Janel") believes that the disclosures made are adequate to make the information presented not misleading. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary
to a fair statement of the results for the interim periods presented. The results of operations for the periods presented are not necessarily indicative of the results to be expected for a full fiscal year, or any other period. These consolidated
financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Form 10-K as filed with the Securities and Exchange Commission.
Business description
Janel is a holding company that had the following two reportable segments at September 30, 2018: Global Logistics Services and Manufacturing. Effective October 1, 2018, the Company realigned its Manufacturing segment, which was separated into two
segments named Manufacturing and Life Sciences. Accordingly, the Company’s current structure consists of the following three reportable segments: (1) Global Logistics Services, (2) Manufacturing and (3) Life Sciences. The Company has reported its
segment results for all periods presented under the realigned business segments for the prior year to be consistent with the current presentation, as reflected in note 12.
A management group at the holding company level (the “corporate group”) focuses on significant capital allocation decisions and corporate governance and supporting Janel’s
subsidiaries where appropriate. Janel expects to grow through its subsidiaries’ organic growth and by completing acquisitions. We plan to either acquire businesses within our existing segments or expand our portfolio into new strategic segments.
Our acquisition strategy focuses on reasonably-priced companies with strong and capable management teams, attractive existing business economics and stable and predictable earnings power.
Global Logistics Services
The Company's Global Logistics Services segment is comprised of several wholly-owned subsidiaries, collectively known as "Janel Group." Janel Group is a non-asset based, full-service provider of cargo
transportation logistics management services, including freight forwarding via air-, ocean- and land-based carriers, customs brokerage services, warehousing and distribution services, and other value-added logistics services.
On November 20, 2018, we completed a business combination whereby we acquired the membership interest of Honor Worldwide Logistics, LLC (“Honor”), a global logistics services provider with two U.S. locations. See note 2.
On October 17, 2018, we completed a business combination whereby we acquired substantially all of the assets and certain liabilities of Sea Cargo, Inc. (“Sea Cargo”), a global logistics services provider with one U.S.
location. See note 2.
Manufacturing
The Company’s manufacturing segment is comprised of Indco, Inc. (“Indco”), a majority-owned subsidiary of the Company that manufactures and distributes mixing equipment and apparatus for specific
applications within various industries. Indco’s customer base is comprised of small- to mid-sized businesses as well as repetitive production orders for other larger customers.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
Life Sciences
The Company’s Life Sciences segment is comprised of Aves Labs, Inc. ("Aves") and Antibodies Incorporated ("Antibodies"), which are wholly-owned subsidiaries of the Company. The Company’s Life Sciences segment manufactures
and distributes high-quality monoclonal and polyclonal antibodies, diagnostic reagents and other immunoreagents for biomedical research and provides antibody manufacturing for academic and industry research scientists. Our Life Sciences business also
produces products for other life science companies on an original equipment manufacturer (“OEM”) basis.
On March 5, 2018, the Company acquired all the outstanding common stock of Aves.
On June 22, 2018, the Company acquired all the outstanding common stock of Antibodies.
Basis of consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as Indco, of which Janel owns 91.65%, with a non-controlling interest
held by existing Indco management. The Indco non-controlling interest is mandatorily redeemable and is recorded as a liability. All intercompany transactions and balances have been eliminated in consolidation.
Uses of estimates in the preparation of financial statements
The preparation of financial statements in conformity with generally accepted accounting principles in the United States ("U.S. GAAP") requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements, as well as the reported amounts of revenues and expenses during the reporting period. The most critical
estimates made by the Company are those relating to the potential impairment of goodwill and intangible assets with indefinite lives, the impairment of other long-lived assets, the valuation of acquisitions, the valuation of mandatorily redeemable
non-controlling interests, gain on extinguishment of dividends on our Series C Cumulative Preferred Stock and the realization of deferred tax assets. Actual results could differ from those estimates.
Cash
The Company maintains cash balances at various financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250. The Company's accounts at these institutions may, at
times, exceed the federally insured limits. The Company has not experienced any losses in such accounts.
Accounts receivable and allowance for doubtful accounts receivable
Accounts receivable are recorded at the contractual amount. The Company records its allowance for doubtful accounts based upon its assessment of various factors. The Company considers historical
collection experience, the age of the accounts receivable balances, credit quality of the Company's customers, any specific customer collection issues that have been identified, current economic conditions, and other factors that may affect the
customers' ability to pay. The Company writes off accounts receivable balances that have aged significantly once all collection efforts have been exhausted and the receivables are no longer deemed collectible from the customer. The allowance for
doubtful accounts as of March 31, 2019 and September 30, 2018 was $454 and $124, respectively.
Inventory
Inventory is valued at the lower of cost (using the first-in, first-out method) or net realizable value. The Company maintains an inventory valuation reserve to provide for slow moving and obsolete
inventory, inventory not meeting quality control standards and inventory subject to expiration for its Antibodies business. The products of Antibodies require the initial manufacture of multiple batches to determine if quality standards can
consistently be met. In addition, the Company will produce larger batches of established products than current sales requirements due to economies of scale. The manufacturing process for these products, therefore, has and will continue to produce
quantities in excess of forecasted usage. The Company values acquired manufactured antibody inventory based on a three-year forecast. Inventory quantities in excess of the forecast are not valued due to uncertainty over salability. Amounts are
charged to the reserve when the Company scraps or disposes of inventory.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
Property and equipment and depreciation policy
Property and equipment are recorded at cost. Property and equipment acquired in business combinations are initially recorded at fair value. Depreciation is provided for in amounts sufficient to
amortize the costs of the related assets over their estimated useful lives on the straight-line and accelerated methods for both financial reporting and income tax purposes.
Maintenance and repairs are recorded as expenses when incurred.
Goodwill
The Company records as goodwill the excess of purchase price over the fair value of the tangible and identifiable intangible assets acquired in a business combination. Under current authoritative guidance, goodwill is not
amortized but is tested for impairment annually (on September 30) as well as when an event or change in circumstance indicates impairment may have occurred. Goodwill is tested for impairment by comparing the fair value of the Company's individual
reporting units to their carrying amount to determine if there is potential goodwill impairment. If the fair value of the reporting unit is less than the carrying value, an impairment loss is recorded to the extent that the implied fair value of the
goodwill of the reporting unit is less than its carrying value. The fair value of our reporting units were in excess of carrying value and goodwill was not deemed to be impaired as of September 30, 2018.
Intangibles and long-lived assets
Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In
reviewing for impairment, the carrying value of such assets is compared to the estimated undiscounted future cash flows expected from the use of the assets and their eventual disposition. If such cash flows are not sufficient to support the asset's
recorded value, an impairment charge is recognized to reduce the carrying value of the long-lived asset to its estimated fair value. The determination of future cash flows, as well as the estimated fair value of long-lived assets, involves
significant estimates on the part of management. If there is a material change in economic conditions or other circumstances influencing the estimate of future cash flows or fair value, the Company could be required to recognize impairment charges in
the future. There were no indicators of impairment of long-lived assets during the year ended September 30, 2018.
Business segment information
The Company operates in three reportable segments: Global Logistics Services, Manufacturing and Life Sciences. The Company's Chief Executive Officer regularly reviews financial information at the
reporting segment level in order to make decisions about resources to be allocated to the segments and to assess their performance.
Revenues and revenue recognition
Adoption of ASC Topic 606, "Revenue from Contracts with Customers"
On October 1, 2018, the Company adopted ASU 2014-09, Revenue from Contracts with Customers ("ASC Topic 606"), using the modified retrospective method. Results
for reporting periods beginning on or after October 1, 2018 are presented under ASC Topic 606; however, prior period amounts are not adjusted and continue to be reported in accordance with the accounting standards in effect for those periods.
The Company recorded an increase to the opening balance of retained earnings of $32, net of tax, as of October 1, 2018 due to the cumulative impact of adoption of ASC Topic 606. The impact to revenue and associated cost for the six months ended March 31, 2019 was an increase of $218 and $177, respectively, as a
result of applying ASC Topic 606.
Global Logistics Services
Revenue Recognition
Revenue is recognized upon transfer of control of promised services to customers. With respect to its Global Logistics Services segment, the Company has determined that in general
each shipment transaction or service order constitutes a separate contract with the customer. When the Company provides multiple services to a customer, different contracts may be present for different services.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
The Company typically satisfies its performance obligations as services are rendered at a point in time. A typical shipment would include services rendered at origin, such as pick-up and delivery to port, freight
services from origin to destination port and destination services, such as customs clearance and final delivery. The Company measures the performance of its obligations as services are completed at a point in time during the life of a shipment,
including services at origin, freight and destination. The Company fulfills nearly all of its performance obligations within a one-to two-month-period.
The Company evaluates whether amounts billed to customers should be reported as gross or net revenue. Generally, revenue is recorded on a gross basis when the Company is primarily responsible for fulfilling the promise
to provide the services, when it has discretion in setting the prices for the services to the customers, and the Company has the ability to direct the use of the services provided by the third party. Revenue is recognized on a net basis when we do
not have latitude in carrier selection or establish rates with the carrier.
In the Global Logistics Services segment, the Company disaggregates its revenues by its four primary service categories: ocean import and export, freight
forwarding, customs brokerage and air import and export.
A summary of the Company’s revenues disaggregated by major service lines for the three and six months ended March 31, 2019 was as follows:
Three Months Ended
March 31,
|
Six Months Ended
March 31,
|
|||||||
Service Type
|
2019
|
2019
|
||||||
Ocean import and export
|
$
|
6,539
|
$
|
14,300
|
||||
Freight forwarding
|
5,097
|
9,690
|
||||||
Custom brokerage
|
2,138
|
4,427
|
||||||
Air import and export
|
3,091
|
7,253
|
||||||
Total
|
$
|
16,865
|
$
|
35,670
|
Manufacturing and Life Sciences
Revenues from Indco are derived from the engineering, manufacture and delivery of specialty mixing equipment. Revenues from Aves are derived from the sale of high-quality antibodies and other
immunoreagents for biomedical research and antibody manufacturing. Revenues from Antibodies are derived from the sale of high-quality monoclonal and polyclonal antibodies, diagnostic reagents and diagnostic kits and other immunoreagents for
biomedical research and antibody manufacturing. Payments are received either by credit card or invoice by Indco, Aves and Antibodies. A significant portion of Indco sales comes from print- and web-based catalog and specification features. Such
online sales are generally credit card purchases. Revenues from Indco, Aves and Antibodies are recognized when products are shipped and risk of loss is transferred to the carrier(s) used.
Income (loss) per common share
Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding, excluding unvested restricted stock, during the
period. Diluted net income (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or warrants or the vesting of restricted stock units. The
treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net income (loss) per share when their effect is anti-dilutive.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
Stock-based compensation to employees
Equity classified share-based awards
The Company recognizes compensation expense for stock-based payments granted based on the grant-date fair value estimated in accordance with ASC Topic 718, "Compensation-Stock Compensation." For
employee stock-based awards, we calculate the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for restricted shares; the expense is recognized over the service
period for awards expected to vest.
Stock-based compensation to non-employees
Liability classified share-based awards
The Company maintains other share unit compensation grants for shares of Indco, the Company's majority owned subsidiary, which vest over a period of up to three years following their grant. The shares
contain certain put features where the Company is either required or expects to settle vested awards on a cash basis.
These awards are classified as liability awards, measured at fair value at the date of grant and re-measured at fair value at each reporting date up to and including the settlement date. The
determination of the fair value of the share units under these plans is described in note 9. The fair value of the awards is expensed over the respective vesting period of the individual awards with recognition of a corresponding liability. Changes
in fair value after vesting are recognized through compensation expense. Compensation expense reflects estimates of the number of instruments expected to vest. The impact of forfeitures and fair value revisions, if any, are recognized in earnings
such that the cumulative expense reflects the revisions, with a corresponding adjustment to the settlement liability. Liability-classified share unit liabilities due within 12 months of the reporting date are presented in trade and other payables
while settlements due beyond 12 months of the reporting date are presented in non-current liabilities.
Non-employee share-based awards
The Company accounts for stock-based compensation to non-employees and consultants in accordance with the provisions of ASC 505-50, "Equity-Based Payments to Non-employees." Measurement of share-based
payment transactions with non-employees are based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of share-based payment transactions is determined
at the earlier of performance commitment date or performance completion date. The Company believes that the fair value of the stock-based award is more reliably measurable than the fair value of the services received. The fair value of the granted
stock-based awards is remeasured at each reporting date and expense is recognized over the vesting period of the award.
Mandatorily Redeemable Non-Controlling Interests
The non-controlling interests that are reflected as mandatorily redeemable non-controlling interests in the consolidated financial statements consist of non-controlling interests related
to the Indco acquisition whose owners have certain redemption rights that allow them to require the Company to purchase the non-controlling interests of those owners upon certain events outside the control of the Company, including upon the death of the holder. The Company is required to purchase 20% of the 8.35% mandatorily redeemable non-controlling interest at the option of the holder beginning on the third anniversary of the date of the Indco
acquisition, which was March 21, 2019. On the date the Company acquires the controlling interest in a business combination, the fair value of the non-controlling interest is recorded in the long-term
liabilities section of the consolidated balance sheet under the caption "Mandatorily redeemable non-controlling interest." The mandatorily redeemable
non-controlling interest is adjusted each reporting period, if required, to its then current redemption value, based on the predetermined formula defined in the respective agreement. The Company reflects any adjustment in the redemption value and
any earnings attributable to the mandatorily redeemable non-controlling interest in its consolidated statements of operations by recording the adjustments and earnings to other income and expense in the caption "change in fair value of mandatorily redeemable non-controlling interest."
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
Income taxes
The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, "Income Taxes." Under this method, income tax expense is recognized for the amount of:
(i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements or tax returns. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax
rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate
realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken
or expected to be taken in the Company's income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
On December 22, 2017, the United States enacted tax reform legislation through the Tax Cuts and Jobs Act (the "Tax Reform Act"), which significantly changed the existing U.S. tax laws, including a
reduction in the corporate tax rate from 34% to 21%, a move from a worldwide tax system to a territorial system, as well as other changes. As a result of the enactment of the Tax Reform Act, the Company recorded an income tax benefit of $28 in
fiscal 2018 related to the re-measurement of certain deferred tax assets, primarily net operating losses and intangibles.
Recent accounting pronouncements
Recently adopted accounting pronouncements
In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (“ASC
Topic 606”), to clarify the principles used to recognize revenue for all entities. This new standard requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which the entity expects to be entitled for those goods or services. In addition, the new standard requires enhanced qualitative and quantitative disclosures related to the nature, amount, timing and uncertainty of revenue and cash flows arising from
contracts with customers.
The Company adopted this standard on October 1, 2018 using the modified retrospective approach. As a result of using this approach, the Company recognized the cumulative effect adjustment
to the opening balance of retained earnings. Comparative prior year information has not been adjusted and continues to be reported under the Company's historical revenue recognition policies described in Note 1 to the Company's Form 10-K as
filed on July 26, 2019.
The adoption of this new standard adjusted the revenue recognition timing of the Company's brokerage and transportation management services performance obligation from point in time to over time on a proportionate
transit time basis within the Company’s Global Logistics Services, which resulted in a cumulative transition adjustment to the opening balance of retained earnings on October 1, 2018, of $32, net of tax, and
an increase of $218 and $177 to revenue and cost for the six months ended March 31, 2019, respectively. While adoption of this standard also affected the corresponding direct costs of revenue, this change did
not have a material impact on the Company's consolidated financial statements due to the short-term nature of its performance obligations.
As part of the adoption of this standard, the Company implemented changes to its accounting policies, practices and internal controls over financial reporting.
Recently issued accounting pronouncements not yet adopted
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its
balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the
amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The new lease standard is expected to be adopted using a
modified retrospective transition and will be effective for the Company beginning on October 1, 2019.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
The Company is currently evaluating its existing lease portfolio, including accumulating all of the necessary information required to properly evaluate and account for the leases under this new
standard. The Company anticipates that the adoption of this standard will materially affect the consolidated balance sheets.
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, to simplify the subsequent measurement of goodwill
by eliminating Step 2 from the goodwill impairment test. This new accounting standard will be effective for annual periods beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effects that the adoption of this
guidance will have on its consolidated financial statements.
In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation, which expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods
and services from nonemployees. The amendments in this update will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is evaluating the
effects that the adoption of this guidance will have on its consolidated financial statements.
Reclassifications
Prior year financial statement amounts are reclassified as necessary to conform to the current year presentation. These prior period reclassifications did not affect the Company's net income, earnings
per share, stockholders' equity or working capital.
2. |
ACQUISITIONS
|
Honor Worldwide Logistics, LLC
Through its wholly-owned subsidiary, Janel Group, Inc. (“Janel Group”), the Company acquired the membership interests of Honor Worldwide Logistics LLC (“Honor”) on November 20, 2018 in a transaction pursuant to which
Honor became a direct wholly-owned subsidiary of Janel Group and an indirect wholly-owned subsidiary of the Company. The acquisition of Honor was funded with cash provided by normal operations along with the subordinated promissory note. Honor
provides global logistics services with two U.S. locations in Charleston and Houston and expands the domestic network of the Company's Global Logistics Services segment. The results of operations for Honor are reflected in the Global Logistics
Services reporting segment.
Sea Cargo, Inc.
On October 17, 2018, we completed a business combination whereby we acquired substantially all of the assets and certain liabilities of Sea Cargo, Inc. (“Sea Cargo”), a global logistics services
provider with one U.S. location. The acquisition of Sea Cargo was funded with cash provided by normal operations. This acquisition was completed primarily to expand our services and offerings and was related to our
Global Logistics Services business.
Purchase price allocation
The aggregate purchase price for the Honor and Sea Cargo acquisitions was $2,392, net of $70 of cash received. At closing, $2,006 was paid in cash, a subordinated promissory note in the aggregate
amount of $456 was issued to a former member and $50 was recorded in accrued expenses as a preliminary earnout consideration. In accordance with the acquisition method of accounting, the Company allocated the consideration paid for Honor and Sea
Cargo to the net tangible and identifiable intangible assets based on their estimated fair values. The Company is still finalizing the valuation of assets acquired and liabilities assumed, and, as such, the fair value amounts are preliminary and
subject to change. Primary amounts subject to adjustment include, but are not limited to, intangible assets, fair value of accounts receivable or a change in the goodwill balance. Goodwill represents the excess of the purchase price over the fair
value of the underlying net tangible and identifiable intangible assets.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
3. |
PROPERTY AND EQUIPMENT
|
A summary of property and equipment and the estimated lives used in the computation of depreciation and amortization is as follows:
March 31,
2019
|
September 30,
2018
|
Life
|
|||||||
Building and Improvements
|
$
|
2,547
|
$
|
2,366
|
15-30 Years
|
||||
Land and Improvements
|
823
|
823
|
Indefinite
|
||||||
Furniture & Fixtures
|
225
|
211
|
3-7 Years
|
||||||
Computer Equipment
|
339
|
323
|
3-5 Years
|
||||||
Machinery & Equipment
|
798
|
764
|
3-15 Years
|
||||||
Leasehold Improvements
|
181
|
181
|
Shorter of Lease Term or Asset Life
|
||||||
4,913
|
4,668
|
||||||||
Less: Accumulated Depreciation
|
(1,010
|
)
|
(881
|
)
|
|||||
3,903
|
$
|
3,787
|
Depreciation expense for the six months ended March 31, 2019 and 2018 was $152 and $51, respectively.
4.
|
INVENTORY
|
Inventories consisted of the following:
March 31,
2019
|
September 30,
2018
|
|||||||
Finished Goods
|
$
|
1,102
|
$
|
1,241
|
||||
Work-in-Process
|
263
|
286
|
||||||
Raw Materials
|
1,052
|
888
|
||||||
Less - Reserve for Inventory Valuation
|
(25
|
)
|
(24
|
)
|
||||
Inventory Net
|
$
|
2,392
|
$
|
2,391
|
5.
|
INTANGIBLE ASSETS
|
A summary of intangible assets and the estimated useful lives used in the computation of amortization is as follows:
March 31,
2019
|
September 30,
2018
|
Life
|
|||||||
Customer Relationships
|
$
|
13,032
|
$
|
12,052
|
15-20 Years
|
||||
Trademarks / Names
|
2,141
|
2,118
|
20 Years
|
||||||
Other
|
708
|
656
|
2-5 Years
|
||||||
15,881
|
14,826
|
||||||||
Less: Accumulated Amortization
|
(2,923
|
)
|
(2,479
|
)
|
|||||
$
|
12,958
|
$
|
12,347
|
Amortization expense for the six months ended March 31, 2019 and 2018 was $444 and $394, respectively.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
6.
|
NOTES PAYABLE - BANKS
|
(A)
|
Presidential Financial Corporation Facility
|
On March 27, 2014, Janel Corporation and several of its Janel Group subsidiaries (collectively, the "Janel Borrowers") entered into a Loan and Security Agreement (the "Presidential Loan Agreement")
with Presidential Financial Corporation with respect to a revolving line of credit facility (the "Presidential Facility"). At September 30, 2017, the Presidential Facility provided that the Janel Borrowers could borrow up to $10.0 million, limited
to 85% of the Janel Borrowers' aggregate outstanding eligible accounts receivable, subject to adjustment as set forth in the Presidential Loan Agreement. Interest accrued at an annual rate equal to 5% above the greater of (a) the prime rate of
interest quoted in The Wall Street Journal from time to time, or (b) 3.25%. The Janel Borrowers' obligations under the Presidential Facility were secured by all of the assets of the Janel Borrowers. The Presidential Facility was terminated on
October 17, 2017, and the Company replaced the Presidential Facility with the Santander Bank Facility (see below).
At September 30, 2017, outstanding borrowings under the Presidential Facility were $6,139, representing 80.3% of the $7,643 available thereunder, and interest was accruing at an effective interest
rate of 7.5%. The Janel Borrowers were in compliance with the covenants defined in the Presidential Loan Agreement as of September 30, 2017.
(B)
|
Santander Bank Facility
|
On October 17, 2017, the Janel Group subsidiaries (collectively the "Janel Group Borrowers"), with Janel Corporation as a guarantor, entered into a Loan and Security Agreement (the "Santander Loan
Agreement") with Santander Bank, N.A. ("Santander") with respect to a revolving line of credit facility (the "Santander Facility"). The Santander Facility provides that the Janel Group Borrowers can borrow up to $10,000, limited to 85% of the Janel
Group Borrowers' aggregate outstanding eligible accounts receivable, subject to adjustment as set forth in the Santander Loan Agreement. Interest accrues on the Santander Facility at an annual rate equal to, at the Janel Group Borrowers' option,
Prime plus 0.50%, or LIBOR (30, 60 or 90 day) plus 2.50% subject to a LIBOR floor of 75 basis points. The Janel Group Borrowers' obligations under the Santander Facility are secured by all of the assets of the Janel Group Borrowers. The Santander
Loan Agreement requires, among other things, that the Janel Group Borrowers, on a quarterly basis, maintain a Minimum Debt Service Coverage ratio, as defined in the Santander Loan Agreement. The loan is subject to earlier termination as provided in
the Santander Loan Agreement and matures on October 17, 2020, unless renewed. The Santander Loan Agreement requires the Company to maintain a lock box with Santander in addition to containing certain subjective acceleration clauses. As a result of
these terms, the loan is classified as a current liability on the consolidated balance sheet.
On March 21, 2018, the Janel Group Borrowers, the Company and Aves entered into an amendment with Santander (the "Santander Amendment") with respect to the Santander Loan Agreement. Pursuant to the
Santander Amendment, among other changes Aves was added as a loan party obligor (but not a Janel Group Borrower) under the Santander Loan Agreement, the maximum amount available under the Santander Loan Agreement was increased from $10,000 to
$11,000 (subject to 85% of eligible receivables), the foreign account sublimit was increased from $1,500 to $2,000, a one-time waiver was granted until May 31, 2018 for the stated event of default related to the delivery of the quarterly financial
statements for the fiscal quarter ended December 31, 2017, and a one-time waiver, retroactive to March 5, 2018, of the provision that prohibits the Company from using proceeds of the revolving loan to finance acquisitions was granted for the
purpose of partially funding the acquisition of Aves.
On November 20, 2018, the Company and its wholly-owned subsidiaries entered into the Limited Waiver, Joinder and Second Amendment (“Amendment No. 2”) to the Santander Loan Agreement (as amended by the
Santander Amendment), with Santander Bank, N.A. Pursuant to, and among other changes affected by, Amendment No. 2: (1) Honor Worldwide Logistics LLC, HWL Brokerage LLC and Global Trading Resources Inc. were added as new borrowers under the
Santander Loan Agreement; (2) Aves was released as a loan party obligor under the Santander Loan Agreement; (3) the maximum revolving facility amount available was increased from $11,000 to $17,000 (limited to 85% of the borrowers’ eligible
accounts receivable borrowing base and reserves); (4) the foreign account sublimit was increased from $2,000 to $2,500; (5) the letter of credit limit was increased from $500 to $1,000; (6) the definitions of “Debt Service Coverage Ratio,” “Debt
Service Coverage Ratio (Borrower Group)” and “Loan Party” were restated; (7) the permitted acquisition debt basket was increased from $2,500 to $4,000; and (8) the permitted indebtedness basket was increased from $500 to $1,000.
At March 31, 2019, outstanding borrowings under the Santander Facility were $11,970, representing 70.4% of the $17,000 available thereunder, and interest was accruing at an effective interest rate of 5.75%. As of May 1, 2019, Santander had granted the Janel Group Borrowers a one-time waiver until July 31, 2019 for an event of default related to the delivery of the audited financial statements for the fiscal year ended September
30, 2018. Other than as specifically referenced above, the Janel Group Borrowers were in compliance with the covenants defined in the Santander Loan Agreement as of March 31, 2019.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
At September 30, 2018, outstanding borrowings under the Santander Facility were $9,730, representing 88.5% of the $11,000 available thereunder, and interest was accruing at an effective interest rate of 5.75%.
(C)
|
First Merchants Bank Credit Facility
|
On March 21, 2016, Indco executed a Credit Agreement (the "First Merchants Credit Agreement") with First Merchants Bank with respect to a $6,000 term loan and $1,500 (limited to the borrowing base and
reserves) revolving loan (together, the "First Merchants Facility"). Interest accrues on the term loan at an annual rate equal to the one-month LIBOR plus either 3.75% (if Indco's cash flow leverage ratio is less than or equal to 2:1) or 4.75% (if
Indco's cash flow leverage ratio is greater than 2:1). Interest accrues on the revolving loan at an annual rate equal to the one-month LIBOR plus 2.75%. Indco's obligations under the First Merchants Facility are secured by all of Indco's assets and
are guaranteed by the Company. The First Merchants Credit Agreement requires, among other things, that Indco, on a monthly basis, not exceed a "maximum total funded debt to EBITDA ratio" and maintain a "minimum fixed charge covenant ratio," both as
defined in the First Merchants Credit Agreement. The First Merchants Facility requires monthly payments until the expiration date on the fifth anniversary of the loan. The loan is subject to earlier termination as provided in the First Merchants
Credit Agreement.
As of September 30, 2018, there were no outstanding borrowings under the revolving loan and $2,713 of borrowings under the term loan, with interest accruing on the term loan at an effective interest rate of 5.85%.
As of March 31, 2019, there were no outstanding borrowings under the revolving loan and $2,140 of borrowings under the term loan, with interest accruing on the term loan at an effective interest rate
of 6.01%. Indco was in compliance with the covenants defined in the First Merchants Credit Agreement at both March 31, 2019 and September 30, 2018.
March 31,
2019
|
September 30,
2018
|
|||||||
Long Term Debt *
|
$
|
2,140
|
$
|
2,713
|
||||
Less Current Portion
|
(857
|
)
|
(857
|
)
|
||||
$
|
1,283
|
$
|
1,856
|
|||||
*Note: Long Term Debt is due in monthly installments of $71 plus monthly interest, at LIBOR plus 3.75% to 4.75% per annum. The note is collateralized by all of Indco's assets and guaranteed by Janel.
|
(D)
|
First Northern Bank of Dixon
|
On June 21, 2018, AB Merger Sub, Inc., a wholly-owned, indirect subsidiary of the Company, entered into a Business Loan Agreement (the "First Northern Loan Agreement") and Promissory Note with First
Northern Bank of Dixon ("First Northern"), with respect to a $2,025 senior secured term loan (the "Senior Secured Term Loan"). The First Northern Loan Agreement and Promissory Note are dated and effective as of June 14, 2018. The proceeds of the
Senior Secured Term Loan were used to fund a portion of the merger consideration to acquire Antibodies. Interest will accrue on the Senior Secured Term Loan at an annual rate based on the five-year Treasury constant maturity (index) plus 2.50%
(margin) for years one through five then adjusted and fixed for years six through ten using the same index and margin. The borrower's and the Company's obligations to First Northern under the First Northern Loan Agreement are secured by certain
real property owned by Antibodies as of the closing of the Antibodies merger. The Senior Secured Term Loan will mature on June 14, 2028 (subject to earlier termination as provided in the First Northern Loan Agreement). The First Northern Loan
Agreement requires, among other things, that the borrowers maintain certain Minimum Debt Service Coverage, Debt to Tangible Net Worth and Tangible Net Worth ratios as defined in the First Northern Loan Agreement.
As of September 30, 2018, the total amount outstanding under the Senior Secured Term Loan was $2,015, of which $1,975 is included in long-term debt and $40 is included in current portion of long-term
debt, with interest accruing at an effective interest rate of 5.28%.
As of March 31, 2019, the total amount outstanding under the Senior Secured Term Loan was $1,995, of which $1,953 is included in long-term debt and $42 is included in current portion of long-term debt, with interest
accruing at an effective interest rate of 5.28%.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
March 31,
2019
|
September 30,
2018
|
|||||||
Long Term Debt *
|
$
|
1,995
|
$
|
2,015
|
||||
Less Current Portion
|
(42
|
)
|
(40
|
)
|
||||
$
|
1,953
|
$
|
1,975
|
|||||
*Note: Long Term Debt is due in monthly installments of $12 plus monthly interest, at 5.28% per annum. The note is collateralized by real property owned by Antibodies and guaranteed by Janel.
|
The Company was in compliance with the covenants defined in the First Northern Loan Agreement at March 31, 2019 and September 30, 2018.
7.
|
SUBORDINATED PROMISSORY NOTES
|
On June 22, 2018, in connection with the Antibodies acquisition, AB HoldCo, Inc. ("AB HoldCo"), a wholly-owned subsidiary of the Company, entered into two subordinated promissory notes ("AB HoldCo
Subordinated Promissory Notes") with certain former shareholders of Antibodies. Both of the AB HoldCo Subordinated Promissory Notes are guaranteed by the Company and are subordinate to the terms of any credit agreement, loan agreement, indenture,
promissory note, guaranty or other debt instrument pursuant to which AB HoldCo or any affiliate of AB HoldCo incurs, borrows, extends, guarantees, renews or refinances any indebtedness for borrowed money or other extensions of credit with any
federal or state bank or other institutional lender and are unsecured. Each of the AB HoldCo Subordinated Promissory Notes has a 4% annual interest rate payable in arrears on the last business day of each calendar quarter, commencing on September
30, 2018, and has a maturity date of June 22, 2021. The outstanding principal amount of these notes is payable in a single payment on the three-year anniversary date of June 22, 2021. Both notes are subject to prepayment in whole or in part,
without premium or penalty, of the outstanding principal amount of the notes, together with all accrued but unpaid interest on such principal amount up to the date of prepayment. Any prepayment shall be applied first to accrued but unpaid interest,
and then to outstanding principal.
As of March 31, 2019 and September 30, 2018, amounts outstanding under the two AB HoldCo Subordinated Promissory Notes were $47 and $297, respectively.
On November 20, 2018, in connection with the Honor acquisition, Janel Group, a wholly-owned subsidiary of the Company, entered into a subordinated promissory note ("Janel Group Subordinated Promissory
Note") with a former owner of Honor. The Janel Group Subordinated Promissory Note is guaranteed by the Company. The Janel Group Subordinated Promissory Note is subordinate to and junior in right of payment for principal interest premiums and other
amounts payable to the Santander Bank Facility and the First Merchants Bank Credit Facility. The Janel Group Subordinated Promissory Note, has a 6.75% annual interest rate, payable in twelve equal
consecutive quarterly installments of principal and interest, and shall be due and payable on the last day of January, April, July and October beginning in January 2019 each in the amount of $42. The outstanding principal and accrued and unpaid
interest are payable in a single payment on the three-year anniversary date of November 20, 2021. The note is subject to prepayment in whole or in part, without premium or penalty, of the outstanding principal amount of the notes, together with all
accrued but unpaid interest on such principal amount up to the date of prepayment. Any prepayment shall be applied first to accrued but unpaid interest, and then to outstanding principal.
As of March 31, 2019, amount outstanding under the Janel Group Subordinated Promissory Note was $420.
8.
|
STOCKHOLDERS’ EQUITY
|
Janel is authorized to issue 4,500,000 shares of common stock, par value $0.001. In addition, the Company is authorized to issue 100,000 shares of preferred stock, par value $0.001. The preferred
stock is issuable in series with such voting rights, if any, designations, powers, preferences and other rights and such qualifications, limitations and restrictions as may be determined by the Company's board of directors or a duly authorized
committee thereof, without stockholder approval. The board of directors may fix the number of shares constituting each series and increase or decrease the number of shares of any series.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
(A)
|
Preferred Stock
|
Series A Convertible Preferred Stock
Shares of the Company’s Series A Convertible Preferred Stock (the “Series A Stock”) are convertible into shares of the Company’s $0.001 par value common stock at any time on a one-share for one-share
basis. The Series A Stock pays a cumulative cash dividend at a rate of $15 per year, payable quarterly. On September 24, 2018, the 20,000 shares of Series A Stock then outstanding were repurchased by the Company for $400. On September 27, 2018, all
outstanding shares of the Series A Stock were retired.
Series B Convertible Preferred Stock
Shares of the Company’s Series B Convertible Preferred Stock (the "Series B Stock") are convertible into shares of the Company's $0.001 par value common stock at any time on a one-share (of Series B
Stock) for ten-shares (of common stock) basis.
Series C Cumulative Preferred Stock
Shares of the Company’s Series C Cumulative Preferred Stock were initially entitled to receive annual dividends at a rate of 7% per annum of the original issuance price of $10, when and if declared by the Company’s board
of directors, with such rate to increase by 2% annually beginning on the third anniversary of issuance of such Series C Stock to a maximum rate of 13%. By the filing of the Certificate of Amendment on October 17, 2017, the annual dividend rate
decreased to 5% per annum of the original issuance price, when and if declared by the Company’s board of directors, with such rate to increase by 1% annually beginning on January 1, 2019 and on each January 1 thereafter for four years to a maximum
rate of 9%. The dividend rate of the Series C Stock as of September 30, 2018 and 2017 was 5% and 7%, respectively. In the event of liquidation, holders of Series C Stock shall be paid an amount equal to the original issuance price, plus any accrued
but unpaid dividends thereon. Shares of Series C Stock may be redeemed by the Company at any time upon notice and payment of the original issuance price, plus any accrued but unpaid dividends thereon. The liquidation value of Series C Stock was
$12,240 and $11,966 as of March 31, 2019 and September 30, 2018, respectively. The change in terms were deemed to be substantial from a quantitative perspective (greater than 10% change in the present value of future cash flows) as well as
qualitatively when considering the change in the form of the security from original issuance through October 17, 2017. The fair value prior to modification was $8,224 and $6,912 after modification, for a change of $1,312. In accordance with ASC
260, “Earnings Per Share,” this incremental benefit is treated as an adjustment to EPS for common stockholders. The amendment on October 17, 2017 to the annual dividend rate decrease was treated as an extinguishment for accounting purposes in a
manner similar to a dividend.
On March 21, 2018, the Company sold 3,000 shares of the Series C Stock to an accredited investor at a purchase price of $500 per share, or an aggregate of $1,500. On June 22, 2018, the Company sold
2,795 shares of the Series C Stock to an accredited investor at a purchase price of $500 per share, or an aggregate of $1,398. Such shares issued on March 21, 2018 and June 22, 2018 were sold in private placements in reliance upon the exemption
from registration provided by Section 4(a)(2) of the Securities Act of 1933 and Regulation D promulgated thereunder.
For the six months ended March 31, 2019 and 2018, the Company declared dividends on Series C Stock of $270 and $197, respectively.
(B)
|
Equity Incentive Plan
|
On May 12, 2017, the Company adopted the 2017 Equity Incentive Plan (the "2017 Plan") pursuant to which (i) incentive stock options, (ii) non-statutory stock options, (iii) restricted stock awards and
(iv) stock appreciation rights with respect to shares of the Company's common stock may be granted to directors, officers, employees of and consultants to the Company. Participants and all terms of any awards under the Plan are at the discretion of
the Company's board of directors in its role as the Compensation Committee. The 2017 Plan was amended and restated on May 8, 2018, as discussed in more detail in note 9.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
9.
|
STOCK-BASED COMPENSATION
|
On October 30, 2013, the board of directors of the Company adopted the Company’s 2013 Non-Qualified Stock Option Plan (the "2013 Option Plan") providing for options to purchase up to 100,000 shares of
common stock for issuance to directors, officers, employees of and consultants to the Company and its subsidiaries.
On May 12, 2017, the board of directors adopted the Company's 2017 Equity Incentive Plan (the "2017 Plan") pursuant to which (i) incentive stock options, (ii) non-statutory stock options, (iii)
restricted stock awards and (iv) stock appreciation rights with respect to up to 100,000 shares of the Company's common stock may be granted to directors, officers, employees of and consultants to the Company.
On May 8, 2018, the board of directors of Janel amended and restated the 2017 Plan (as amended and restated, the "Amended 2017 Plan"). The provisions and terms of the Amended 2017 Plan are the same as
those in the 2017 Plan, except that the Amended 2017 Plan removes the ability of Janel to award incentive stock options and removes the requirement for stockholder approval of the 2017 Plan.
Total stock-based compensation for the six months ended March 31, 2019 and 2018 amounted to $172 and $296, respectively, and was included in selling, general and administrative expense in the
Company's statements of operations.
(A)
|
Stock Options
|
The Company uses the Black-Scholes option pricing model to estimate the fair value of our share-based awards. In applying this model, we use the following assumptions:
• |
Risk-free interest rate - We determine the risk-free interest rate by using a weighted average assumption equivalent to the expected term based on the U.S. Treasury constant maturity rate.
|
• |
Expected volatility - We estimate expected volatility using daily historical trading data of a peer group.
|
The fair values of our employee option awards were estimated using the assumptions below, which yielded the following weighted average grant date fair values for the periods presented:
Six Months Ended
March 31,
2019 |
||||
Risk-free Interest Rate
|
3.04
|
%
|
||
Expected Option Term in Years
|
5.5-6.5
|
|||
Expected Volatility
|
95.4% - 98.8
|
%
|
||
Dividend Yield
|
0
|
%
|
||
Weighted Average Grant Date Fair Value
|
$
|
7.75
|
Number of
Options
|
Weighted Average
Exercise Price
|
Weighted Average
Remaining Contractual
Term (in years)
|
Aggregate Intrinsic
Value (in thousands)
|
|||||||||||||
Outstanding Balance at September 30, 2018
|
112,798
|
$
|
5.09
|
6.9
|
$
|
357.10
|
||||||||||
Granted
|
7,500
|
$
|
7.75
|
9.5
|
$
|
12.50
|
||||||||||
Exercised
|
(1,500
|
)
|
$
|
3.25
|
-
|
$
|
-
|
|||||||||
Outstanding Balance at March 31, 2019
|
118,798
|
$
|
5.28
|
6.6
|
$
|
485.84
|
||||||||||
Exercisable on March 31, 2019
|
98,711
|
$
|
4.73
|
6.2
|
$
|
458.22
|
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
The aggregate intrinsic value in the above table was calculated as the difference between the closing price of the Company's common stock at March 31, 2019 of $9.37 per share and the exercise price of
the stock options that had strike prices below such closing price.
As of March 31, 2019, there was approximately $48 of total unrecognized compensation expense related to the unvested employee stock options which
is expected to be recognized over a weighted average period of less than one year.
The fair values of our non-employee option awards as of March 31, 2019 were estimated using the assumptions below, which yielded the following weighted average grant date fair values for the periods
presented:
Six Months Ended
March 31,
2019
|
||||
Risk-free Interest Rate
|
2.31
|
%
|
||
Expected Option Term in Years
|
7.5-8.4
|
|||
Expected Volatility
|
96.39
|
%
|
||
Dividend Yield
|
0
|
%
|
||
Weighted Average Grant Date Fair Value
|
$
|
4.13 - $8.04
|
Number of
Options
|
Weighted Average
Exercise Price
|
Weighted Average
Remaining Contractual
Term (in years)
|
Aggregate Intrinsic
Value (in thousands)
|
|||||||||||||
Outstanding Balance at September 30, 2018
|
51,053
|
$
|
7.58
|
8.8
|
$
|
31.84
|
||||||||||
Granted
|
-
|
$
|
-
|
-
|
$
|
-
|
||||||||||
Outstanding Balance at March 31, 2019
|
51,053
|
$
|
7.58
|
8.3
|
$
|
91.57
|
||||||||||
Exercisable on March 31, 2019
|
19,036
|
$
|
7.21
|
8.2
|
$
|
41.10
|
The aggregate intrinsic value in the above table was calculated as the difference between the closing price of our common stock at March 31, 2019, of $9.37 per share and the exercise price of the
stock options that had strike prices below such closing price.
As of March 31, 2019, there was approximately $85 of total unrecognized compensation expense related to the unvested stock options, which is expected to be recognized over a weighted average period of
less than one year.
Liability classified share-based awards
Additionally, during the six months ended March 31, 2019, 6,812 options were granted with respects to Indco's common stock. The Company uses the Black-Scholes option pricing model to estimate the fair
value of Indco's share-based awards. In applying this model, the Company used the following assumptions:
2019
|
||||
Risk-free Interest Rate
|
2.78
|
%
|
||
Expected Option Term in Years
|
4.02 - 6.27
|
|||
Expected Volatility
|
98.5% - 102.9
|
%
|
||
Dividend Yield
|
0
|
%
|
||
Weighted Average Grant Date Fair Value
|
$
|
12.07
|
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
Number of
Options
|
Weighted Average
Exercise Price
|
Weighted Average
Remaining Contractual
Term (in years)
|
Aggregate Intrinsic
Value (in thousands)
|
|||||||||||||
Outstanding Balance at September 30, 2018
|
25,321
|
$
|
7.97
|
8.0
|
$
|
105.36
|
||||||||||
Granted
|
6,812
|
$
|
12.13
|
12.1
|
$
|
-
|
||||||||||
Outstanding Balance at March 31, 2019
|
32,133
|
$
|
8.85
|
8.9
|
$
|
105.36
|
||||||||||
Exercisable on March 31, 2019
|
20,825
|
$
|
7.08
|
7.1
|
$
|
105.09
|
The aggregate intrinsic value in the above table was calculated as the difference between the valuation price of Indco's common stock at March 31, 2019 of $12.13 per share and the exercise price of
the stock options that had strike prices below such closing price.
The liability classified awards were measured at fair value at each reporting date until the final measurement date, which was the date of completion of services required to earn the option. The
compensation cost related to these options was approximately $64 and $172 for the six months ended March 31, 2019 and fiscal year ended September 30, 2018, respectively, and is included in other liabilities in the consolidated financial statement.
The cost associated with the options issued on each grant date is being recognized ratably over the period of service required to earn each tranche of options.
Upon vesting, the options continue to be accounted for as a liability in accordance with ASC 480-10-25-8 and are measured in accordance with ASC 480-10-35 at every reporting period until the options
are settled. Changes in the fair value of the vested options are recognized in earnings in the consolidated financial statements.
The options are classified as liabilities, and the underlying shares of Indco's common stock also contain put options which result in their classification as a mandatorily redeemable security. While
their redemption does not occur on a fixed date, there is an unconditional obligation for the Company to repurchase the shares upon death, which is certain to occur at some point in time.
As of March 31, 2019, there was approximately $70 of total unrecognized compensation expense related to the unvested Indco stock options. This expense is expected to be recognized over a weighted
average period of less than one year.
(B)
|
Restricted Stock
|
During the six months ended March 31, 2019, there were no shares of restricted stock granted. Under the Amended 2017 Plan, each grant of restricted stock vests over a three-year period and the cost to
the recipient is zero. Restricted stock compensation expense, which is a non-cash item, is being recognized in the Company's financial statements over the vesting period of each restricted stock grant.
The following table summarizes the status of our employee unvested restricted stock under the Amended 2017 Plan for the six months ended March 31, 2019:
Restricted Stock
|
Weighted Average
Grant Date Fair Value
|
|||||||
Unvested at September 30, 2018
|
10,000
|
$
|
8.01
|
|||||
Vested
|
(5,000
|
)
|
$
|
8.01
|
||||
Unvested at March 31, 2019
|
5,000
|
$
|
8.01
|
As of March 31, 2019, there was approximately $8 of total unrecognized compensation cost related to unvested employee restricted stock. The cost is expected to be recognized over a weighted-average
period of approximately 1.3 years.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
The following table summarizes the status of our non-employee unvested restricted stock under the Amended 2017 Plan for the six months ended March 31, 2019:
Restricted Stock
|
Weighted Average
Grant Date Fair Value
|
|||||||
Unvested at September 30, 2018
|
30,000
|
$
|
8.03
|
|||||
Vested
|
(3,333
|
)
|
$
|
8.01
|
||||
Unvested at March 31, 2019
|
26,667
|
$
|
8.04
|
As of March 31, 2019, there was approximately $81 of unrecognized compensation cost related to non-employee unvested restricted stock. The cost is expected to be recognized over a weighted-average period of approximately
1.6 years.
As of March 31, 2019, included in accrued expenses and other current liabilities was $236 which represents 28,333 shares of restricted stock that vested but not issued.
10.
|
INCOME PER COMMON SHARE
|
The following table provides a reconciliation of the basic and diluted income (loss) per share ("EPS") computations for the three and six months ended March 31, 2019 and 2018 (in thousands, except share
and per share data):
For the Three Months Ended
March 31,
|
For the Six Months Ended
March 31,
|
|||||||||||||||
2019
|
2018
|
2019
|
2018
|
|||||||||||||
Income:
|
||||||||||||||||
Net income (loss)
|
$
|
175
|
$
|
(217
|
)
|
$
|
719
|
$
|
(37
|
)
|
||||||
Gain on extinguishment of Preferred stock Series C dividends
|
-
|
-
|
-
|
1,312
|
||||||||||||
Preferred stock dividends
|
(148
|
)
|
(91
|
)
|
(270
|
)
|
(197
|
)
|
||||||||
Net Income (loss) availible to common stockholders
|
$
|
27
|
$
|
(308
|
)
|
$
|
449
|
$
|
1,078
|
|||||||
Common Shares:
|
||||||||||||||||
Basic - weighted average common shares
|
847,784
|
568,974
|
847,621
|
565,629
|
||||||||||||
Effect of dilutive securities:
|
||||||||||||||||
Stock options
|
51,097
|
-
|
54,644
|
-
|
||||||||||||
Restricted stock
|
20,369
|
-
|
19,162
|
-
|
||||||||||||
Convertible preferred stock
|
12,710
|
-
|
12,710
|
-
|
||||||||||||
Diluted - weighted average common stock
|
$
|
931,960
|
$
|
568,974
|
$
|
934,137
|
$
|
565,629
|
||||||||
Income per Common Share:
|
||||||||||||||||
Basic -
|
||||||||||||||||
Net income (loss)
|
$
|
0.21
|
$
|
(0.38
|
)
|
$
|
0.85
|
$
|
(0.06
|
)
|
||||||
Gain on extinguishment of Preferred stock dividends Series C
|
-
|
-
|
-
|
2.32
|
||||||||||||
Preferred stock dividends
|
(0.17
|
)
|
(0.16
|
)
|
(0.32
|
)
|
(0.35
|
)
|
||||||||
Net Income (loss) availible to common stockholders
|
$
|
0.04
|
$
|
(0.54
|
)
|
$
|
0.53
|
$
|
1.91
|
|||||||
Diluted -
|
||||||||||||||||
Net income (loss)
|
$
|
0.18
|
$
|
(0.38
|
)
|
$
|
0.77
|
$
|
(0.06
|
)
|
||||||
Gain on extinguishment of Preferred stock dividends Series C
|
-
|
-
|
-
|
2.32
|
||||||||||||
Preferred stock dividends
|
(0.15
|
)
|
(0.16
|
)
|
(0.29
|
)
|
(0.35
|
)
|
||||||||
Net income (loss) availible to common stockholders
|
$
|
0.03
|
$
|
(0.54
|
)
|
$
|
0.48
|
$
|
1.91
|
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
The computation for the diluted number of shares excludes unvested restricted stock, unexercised stock options and unexercised warrants that are anti-dilutive. There were 7,153 anti-dilutive shares for
the six-month period ended March 31, 2019 and no anti-dilutive shares for the six month period ended March 31, 2018. Potentially diluted securities as of March 31, 2019 and 2018 are as follows:
March 31,
|
||||||||
2019
|
2018
|
|||||||
Employee Stock Options
|
118,798
|
112,798
|
||||||
Non-employee Stock Options
|
51,053
|
51,053
|
||||||
Employee Restricted Stock
|
5,000
|
10,000
|
||||||
Non-employee Restricted Stock
|
26,667
|
41,666
|
||||||
Warrants
|
-
|
250,000
|
||||||
Convertible Preferred Stock
|
12,710
|
12,710
|
||||||
214,228
|
478,227
|
11.
|
INCOME TAXES
|
On December 22, 2017, the Tax Cut and Jobs Act ("Tax Reform Act") was signed into law. The Tax Reform Act included significant changes to existing law, including among other items, a reduction to the
U.S. federal statutory corporate tax rate from 34% to 21% effective January 1, 2018. ASC 740, "Income Taxes ("ASC 740"), requires that the effects of changes in tax laws or rates be recognized in the period in which the law is enacted. Those effects,
both current and deferred, are reported as part of the tax provision, regardless of income in which the underlying pretax income (expense) or asset (liability) was or will be reported.
The Company's estimated fiscal 2019 blended U.S. federal statutory corporate income tax rate of 26.1% was applied in the computation of the income
tax provision for the three months ended March 31, 2019. The blended U.S. federal statutory corporate tax rate of 24.2% represents the weighted average of the pre-enactment U.S. federal statutory corporate tax
rate of 34% prior to the January 1, 2018 effective date and the post-enactment U.S. federal statutory corporate tax rate of 21% thereafter.
12.
|
BUSINESS SEGMENT INFORMATION
|
As discussed above in note 1, the Company had the following two reportable segments at September 30, 2018: Global Logistics Services and Manufacturing. Effective October 1, 2018, the Company realigned
its Manufacturing segment, which was separated into two segments named Manufacturing and Life Sciences. Accordingly, the Company now operates in three reportable segments: 1) Global Logistics Services, 2) Manufacturing and 3) Life Sciences,
supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company's reportable segments for the three and six months ended March 31, 2019:
For the three months ended March 31, 2019
|
Consolidated
|
Global
Logistics
Services
|
Manufacturing
|
Life Sciences
|
Corporate
|
|||||||||||||||
Revenue
|
$
|
20,969
|
$
|
16,865
|
$
|
2,452
|
$
|
1,652
|
$
|
-
|
||||||||||
Forwarding expenses and cost of revenues
|
14,599
|
12,957
|
1,077
|
565
|
-
|
|||||||||||||||
Gross profit
|
6,370
|
3,908
|
1,375
|
1,087
|
-
|
|||||||||||||||
Selling, general and administrative
|
5,692
|
3,468
|
759
|
724
|
741
|
|||||||||||||||
Amortization of intangible assets
|
236
|
-
|
-
|
-
|
236
|
|||||||||||||||
Income (loss) from Operations
|
442
|
440
|
616
|
363
|
(977
|
)
|
||||||||||||||
Interest expense, net
|
198
|
127
|
36
|
37
|
(2
|
)
|
||||||||||||||
Identifiable assets
|
55,348
|
20,825
|
2,418
|
6,672
|
25,433
|
|||||||||||||||
Capital expenditures
|
71
|
2
|
-
|
69
|
-
|
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
For the six months ended March 31, 2019
|
Consolidated
|
Global
Logistics
Services
|
Manufacturing
|
Life Sciences
|
Corporate
|
|||||||||||||||
Revenue
|
$
|
43,296
|
$
|
35,670
|
$
|
4,533
|
$
|
3,093
|
$
|
-
|
||||||||||
Forwarding expenses and cost of revenues
|
30,439
|
27,375
|
2,010
|
1,054
|
-
|
|||||||||||||||
Gross profit
|
12,857
|
8,295
|
2,523
|
2,039
|
-
|
|||||||||||||||
Selling, general and administrative
|
11,081
|
6,828
|
1,467
|
1,431
|
1,355
|
|||||||||||||||
Amortization of intangible assets
|
444
|
-
|
-
|
-
|
444
|
|||||||||||||||
Income (loss) from Operations
|
1,332
|
1,467
|
1,056
|
608
|
(1,799
|
)
|
||||||||||||||
Interest expense, net
|
360
|
225
|
76
|
64
|
(5
|
)
|
||||||||||||||
Identifiable assets
|
55,348
|
20,825
|
2,418
|
6,672
|
25,433
|
|||||||||||||||
Capital expenditures
|
253
|
16
|
41
|
196
|
As of March 31, 2018, the Company operated in two reportable segments, Global Logistics Services and Manufacturing, supported by a corporate group which conducts activities that are non-segment
specific. The following table presents selected financial information about the Company's reportable segments for the three and six months ended March 31, 2018:
For the three months ended March 31, 2018
|
Consolidated
|
Global
Logistics
Services
|
Manufacturing
|
Life Sciences
|
Corporate
|
|||||||||||||||
Revenue
|
$
|
15,870
|
$
|
13,695
|
$
|
2,094
|
$
|
81
|
$
|
-
|
||||||||||
Forwarding expenses and cost of revenues
|
11,029
|
10,169
|
820
|
40
|
-
|
|||||||||||||||
Gross profit
|
4,841
|
3,526
|
1,274
|
41
|
-
|
|||||||||||||||
Selling, general and administrative
|
4,781
|
3,027
|
897
|
31
|
826
|
|||||||||||||||
Amortization of intangible assets
|
201
|
-
|
-
|
-
|
201
|
|||||||||||||||
Income (loss) from Operations
|
(141
|
)
|
499
|
377
|
10
|
(1,027
|
)
|
|||||||||||||
Interest expense
|
117
|
68
|
49
|
-
|
-
|
|||||||||||||||
Identifiable assets
|
40,704
|
12,084
|
2,159
|
1,528
|
24,933
|
|||||||||||||||
Capital expenditures
|
1
|
-
|
1
|
-
|
-
|
For the six months ended March 31, 2018
|
Consolidated
|
Global
Logistics
Services
|
Manufacturing
|
Life Sciences
|
Corporate
|
|||||||||||||||
Revenue
|
$
|
30,650
|
$
|
26,550
|
$
|
4,019
|
$
|
81
|
$
|
-
|
||||||||||
Forwarding expenses and cost of revenues
|
21,219
|
19,631
|
1,548
|
40
|
-
|
|||||||||||||||
Gross profit
|
9,431
|
6,919
|
2,471
|
41
|
-
|
|||||||||||||||
Selling, general and administrative
|
8,880
|
5,784
|
1,668
|
31
|
1,397
|
|||||||||||||||
Amortization of intangible assets
|
394
|
-
|
-
|
-
|
394
|
|||||||||||||||
Income (loss) from Operations
|
157
|
1,135
|
803
|
10
|
(1,791
|
)
|
||||||||||||||
Interest expense, net
|
234
|
135
|
99
|
-
|
-
|
|||||||||||||||
Identifiable assets
|
40,704
|
12,084
|
2,159
|
1,528
|
24,933
|
|||||||||||||||
Capital expenditures
|
38
|
-
|
38
|
-
|
-
|
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
13.
|
RISKS AND UNCERTAINTIES
|
(A)
|
Currency Risks
|
The nature of Janel's operations requires it to deal with currencies other than the U.S. Dollar. As a result, the Company is exposed to the inherent risks of international currency markets and
governmental interference. A number of countries where Janel maintains offices or agent relationships have currency control regulations. The Company attempts to compensate for these exposures by accelerating international currency settlements among
those agents.
(B)
|
Concentration of Credit Risk
|
The Company's assets that are exposed to concentrations of credit risk consist primarily of cash and receivables from customers. The Company places its cash with financial institutions that have high
credit ratings. The receivables from clients are spread over many customers. The Company maintains an allowance for uncollectible accounts receivable based on expected collectability and performs ongoing credit evaluations of its customers' financial
condition.
(C)
|
Legal Proceedings
|
Janel is occasionally subject to claims and lawsuits which typically arise in the normal course of business. While the outcome of these claims cannot be predicted with certainty, management does not
believe that the outcome of any of these legal matters will have a material adverse effect on the Company’s business, results of operations, financial condition or cash flows.
In December 2017, Janel Group received a Notice of Copyright Infringement letter from counsel for Warren Communications News, Inc. (“Warren”), the publisher of the International Trade Today (“ITT”)
newsletter. The letter alleges that Janel Group infringed upon Warren’s registered copyrights in its ITT newsletter. The Company believes it has meritorious defenses to the allegations. The Company is not presently able to reasonably estimate
potential losses, if any, related to the allegations.
14. |
SUBSEQUENT EVENTS
|
As of May 1, 2019, Santander had granted the Janel Group Borrowers a one-time waiver until July 31, 2019 for an event of default related to the delivery of the annual audited financial statements for
the year ended September 30, 2018 under the Santander Loan Agreement. Such event of default was subsequently remedied. The Janel Group Borrowers were in compliance with the covenants defined in the Santander Loan Agreement as of March 31, 2019.
On August 30, 2019, Indco and First Merchants entered into Amendment No. 1 to Credit Agreement modifying the terms of Indco’s credit facilities with First Merchants and extending the maturity date of the credit facilities. Under the revised terms,
the credit facilities will consist of a $5,500 Term Loan and $1,000 (limited to the borrowing base and reserves) Revolving Loan. Interest will accrue on the Term Loan at an annual rate equal to the one-month LIBOR plus either 2.75% (if Indco’s total
funded debt to EBITDA ratio is less than 2:1), or 3.5% (if Indco’s total funded debt to EBITDA ratio is greater than or equal to 2:1). Interest will accrue on the Revolving Loan at an annual rate equal to the one-month LIBOR plus 2.75%. Indco’s
obligations under the First Merchants credit facilities are secured by all of Indco’s assets and are guaranteed by Janel, and Janel’s guarantee of Indco’s obligations is secured by a pledge of Janel’s Indco shares. The First Merchants credit
facilities will expire on August 30, 2024 (subject to earlier termination as provided in the Credit Agreement) unless renewed.
Through its wholly-owned subsidiary, Aves Lab, Inc. (“Aves”), the Company acquired the membership interests of IgG, LLC (“IgG”) on July 1, 2019 in a transaction pursuant to which IgG became a direct wholly-owned subsidiary of Aves and an indirect
wholly-owned subsidiary of the Company.
Through its wholly-owned subsidiary, Aves Lab, Inc. (“Aves”), the Company completed a business combination whereby we acquired all of the equity interests of PhosphoSolutions, LLC and all of the stock of PhosphoSolutions, Inc, (collectively
“Phospho”) on September 6, 2019. The acquisition of Phospho was funded with cash provided by normal operations.
The aggregate purchase price for the IgG and Phospho acquisitions was $4,243, net of $13 of cash received.
Both the IgG and Phospho acquisitions were completed primarily to expand our product offerings in Life Sciences.
The following discussion and analysis should be read in conjunction with our unaudited interim consolidated financial statements and related notes thereto as of and for the six
months ended March 31, 2019, which have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). Amounts presented in this section are in thousands, except share and per share data.
As used throughout this Report, "we," “us”, "our," "Janel," "the Company," "Registrant" and similar words refer to Janel Corporation and its Subsidiaries.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (the “Report”) contains certain forward-looking statements that reflect management's current expectations with respect to our operations, performance, financial
condition, and other developments. These forward-looking statements may generally be identified by the use of the words "may," "will," "intends," "plans," projects," "believes," "should," "expects," "predicts," "anticipates," "estimates," and similar
expressions or the negative of these terms or other comparable terminology. These statements are necessarily estimates reflecting management's best judgment based upon current information and involve a number of risks, uncertainties and assumptions.
We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made, and readers are advised that various factors, including, but not limited to, those set forth elsewhere in this Report, could
affect our financial performance and could cause our actual results for future periods to differ materially from those anticipated or projected. While it is impossible to identify all such factors, such factors include, but are not limited to, those
risks identified in our periodic reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2018.
OVERVIEW
Janel is a holding company with subsidiaries in three business segments: Global Logistics Services, Manufacturing and Life Sciences. The company strives to create shareholder value primarily through
three strategic priorities: supporting its businesses’ efforts to make investments and to build long-term profits; allocating Janel capital at high risk-adjusted rates of return; and attracting and retaining exceptional talent.
A management group at the holding company level (the “corporate group”) focuses on significant capital allocation decisions, corporate governance and supporting Janel’s subsidiaries
where appropriate. Janel expects to grow through its subsidiaries’ organic growth and by completing acquisitions. We plan to either acquire businesses within our existing segments or expand our portfolio into new strategic segments. Our acquisition
strategy focuses on reasonably-priced companies with strong and capable management teams, attractive existing business economics and stable and predictable earnings power.
Global Logistics Services
The Company's Global Logistics Services segment is comprised of several wholly-owned subsidiaries (collectively "Janel Group"). Janel Group is a non-asset based, full-service provider of cargo
transportation logistics management services, including freight forwarding via air-, ocean- and land-based carriers, customs brokerage services, warehousing and distribution services, and other value-added logistics services.
On November 20, 2018, we completed a business combination whereby we acquired the membership interest of Honor Worldwide Logistics, LLC (“Honor”), a global logistics services provider with two U.S. locations.
On October 17, 2018, we completed a business combination whereby we acquired substantially, all of the assets and certain liabilities of Sea Cargo, Inc. (“Sea Cargo”), a global logistics services provider with one U.S.
location.
Manufacturing
The Company's Manufacturing segment is comprised of Indco, Inc. ("Indco”). Indco is a majority-owned subsidiary of the Company that manufactures and distributes mixing equipment and apparatus for specific applications
within various industries. Indco’s customer base is comprised of small- to mid-sized businesses as well as repetitive production orders for other larger customers.
Life Sciences
The Company’s Life Sciences segment is comprised of Aves Labs, Inc. ("Aves") and Antibodies Incorporated ("Antibodies"), which are wholly-owned subsidiaries of the Company. The Company’s Life Sciences segment manufactures
and distributes high-quality monoclonal and polyclonal antibodies, diagnostic reagents and other immunoreagents for biomedical research and provides antibody manufacturing for academic and industry research scientists. Our Life Sciences business also
produces products for other life science companies on an original equipment manufacturer (OEM) basis.
On March 5, 2018, the Company acquired all of the outstanding common stock of Aves.
On June 22, 2018, the Company acquired all the outstanding common stock of Antibodies.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company’s consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions about
future events that affect the amounts reported in the financial statements and accompanying notes. Since future events and their effects cannot be determined with absolute certainty, the determination of estimates requires the exercise of judgment.
Actual results could differ from those estimates, and such differences may be material to the financial statements. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to revenue
recognition, the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources, primarily allowance for doubtful accounts, accruals for transportation and other direct costs, accruals for cargo
insurance, and deferred income taxes. Management bases its estimates on historical experience and on various assumptions which are believed to be reasonable under the circumstances. We reevaluate these significant factors as facts and circumstances
change. Note 1 of the notes to consolidated financial statements included herein includes a summary of the significant accounting policies and methods used in the preparation of our consolidated financial statements. The following is a brief
discussion of certain accounting policies and estimates.
Management believes that the nature of the Company’s business is such that there are a few complex challenges in accounting for operations. Revenue recognition is considered the critical accounting policy due to the
complexity of arranging and managing global logistics and supply-chain management transactions.
Income taxes
The Company uses the asset and liability method of accounting for income taxes in accordance with Accounting Standards Codification Topic 740, “Income Taxes.” Under this method, income tax expense is
recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities
of a change in tax rates is recognized in the results of operations in the period that includes the enactment date.
On December 22, 2017, the United States enacted tax reform legislation through the Tax Cuts and Jobs Act (the “Tax Reform Act”), which significantly changed the existing U.S. tax laws, including by
reducing the corporate tax rate from 34% to 21%, moving from a worldwide tax system to a territorial system as well as other changes. As a result of the enactment of the Tax Reform Act, the Company made a reasonable estimate and recorded an
additional one-time income tax benefit of $49 during the first quarter of fiscal 2018, related to the estimated re-measurement of certain deferred tax assets, primarily net operating losses and deferred tax liabilities attributable to intangible
assets. The Company continues to evaluate the impact the legislation will have on the consolidated financial statements.
Estimates
While judgments and estimates are a necessary component of any system of accounting, the Company’s use of estimates is limited primarily to the following areas that in the aggregate are not a major
component of the Company’s consolidated statements of operations:
• |
accounts receivable valuation;
|
• |
the useful lives of long-term assets;
|
• |
the accrual of costs related to ancillary services the Company provides;
|
• |
accrual of tax expense on an interim basis; and
|
• |
inventory valuation.
|
Management believes that the methods utilized in these areas are consistent in application. Management further believes that there are limited, if any, alternative accounting principles or methods which
could be applied to the Company’s transactions.While the use of estimates means that actual future results may be different from those contemplated by the estimates, the Company believes that alternative principles and methods used for making such
estimates would not produce materially different results than those reported.
Critical Accounting Policies and Estimates Applicable to the Global Logistics Services Segment
Revenue Recognition
Revenues are derived from customs brokerage services and from freight forwarding services.
Customs brokerage services include activities required for the clearance of shipments through government customs regimes, such as preparing required documentation, calculating and providing for payment
of duties and other charges on behalf of customers, arranging required inspections and arranging final delivery.
Freight forwarding may require multiple services, including long-distance shipment via air, ocean or ground assets, destination handling (“break bulk”), warehousing, distribution and other logistics
management activities. As an asset-light business, Janel Group owns none of the assets by which it fulfills its customers’ logistics needs. Rather, it purchases the services its customers need from asset owners, such as airlines and steamship lines,
and resells them. By consolidating shipments from multiple customers, Janel Group can negotiate terms of service with asset owners that are more favorable than those the customers could negotiate themselves.
Revenue is recognized upon transfer of control of promised services to customers. With respect to its Global Logistics Services segment, the Company has determined that in general
each shipment transaction or service order constitutes a separate contract with the customer. When the Company provides multiple services to a customer, different contracts may be present for different services.
The Company typically satisfies its performance obligations as services are rendered at a point in time. A typical shipment would include services rendered at origin, such as pick-up and delivery to port, freight
services from origin to destination port and destination services, such as customs clearance and final delivery. The Company measures the performance of its obligations as services are completed at a point in time during the life of a shipment,
including services at origin, freight and destination. The Company fulfills nearly all of its performance obligations within a one-to-two month period.
The Company evaluates whether amounts billed to customers should be reported as gross or net revenue. Generally, revenue is recorded on a gross basis when the Company is primarily responsible for fulfilling the promise
to provide the services, when it has discretion in setting the prices for the services to the customers, and the Company has the ability to direct the use of the services provided by the third party. Revenue is recognized on a net basis when we do
not have latitude in carrier selection or establish rates with the carrier.
Critical Accounting Policies and Estimates Applicable to the Manufacturing and Life Science Segments
Revenue Recognition
Revenues from Indco are derived from the engineering, manufacture and delivery of specialty mixing equipment. Revenues from Aves are derived from the sale of high-quality antibodies and other
immunoreagents for biomedical research and antibody manufacturing. Revenues from Antibodies are derived from the sale of high-quality monoclonal and polyclonal antibodies, diagnostic reagents and diagnostic kits and other immunoreagents for
biomedical research and antibody manufacturing. Payments are received by either credit card or invoice by Indco, Aves and Antibodies. A significant portion of Indco sales come from print- and web-based catalogs and specification features. Such
online sales are generally credit card purchases. Revenues from Indco, Aves and Antibodies are recognized at a point in time when the performance obligation for goods or services is satisfied and products are shipped with control transferring to
the customer generally upon the transfer of title and risk of loss transfers to the carrier(s) used.
NON-GAAP FINANCIAL MEASURES
While we prepare our financial statements in accordance with U.S. GAAP, we also utilize and present certain financial measures, in particular adjusted operating income, which is not based on or included
in U.S. GAAP (we refer to these as "non-GAAP financial measures").
Net Revenue
Net revenue is a non-GAAP measure calculated as total revenue less forwarding expenses attributable to the Company's Global Logistics Services segment. Our total revenue represents the
total dollar value of services and goods we sell to our customers. Forwarding expenses attributable to the Company’s Global Logistics Services segment refer to purchased transportation and related services including contracted air, ocean, rail,
motor carrier and other costs. Total revenue can be influenced greatly by changes in transportation rates or other items, such as fuel prices, which we do not control.
Management believes that providing net revenue is useful to investors as net revenue is the primary indicator of our ability to source, add value and sell services and products that are provided by
third parties, and we consider net revenue to be our primary performance measurement. The difference between the rate billed to our customers (the sell rate) and the rate we pay to the carrier (the buy rate) is termed “net revenue”, “yield” or
“margin.” As presented, net revenue matches gross margin.
Adjusted Operating Income
As a result of our acquisition strategy, our net income includes material non-cash charges relating to the amortization of customer-related intangible assets in the ordinary course of business as well
as other intangible assets acquired in our acquisitions. Although these charges may increase as we complete more acquisitions, we believe we will be growing the value of our intangible assets such as customer relationships. Because these charges are
not indicative of our operations, we believe that adjusted operating income is a useful financial measure for investors because it eliminates the effect of these non-cash costs and provides an important metric for our business that is more
representative of the actual results of our operations.
Adjusted operating income (which excludes the non-cash impact of amortization of intangible assets, stock-based compensation and amortization of acquired inventory valuation) is used by management as a
supplemental performance measure to assess our business’s ability to generate cash and economic returns.
Adjusted operating income is a non-GAAP measure of income and does not include the effects of preferred stock dividends, interest and taxes.
We believe that net revenue and adjusted operating income provide useful information in understanding and evaluating our operating results in the same manner as management. However, net revenue and
adjusted operating income are not financial measures calculated in accordance with U.S. GAAP and should not be considered as a substitute for total revenue, operation income, or any other operating performance measures calculated in accordance with
U.S. GAAP. Using these non-GAAP financial measures to analyze our business has material limitations because the calculations are based on the subjective determination of management regarding the nature and classification of events and circumstances
that users of the financial statements may find significant.
In addition, although other companies in our industry may report measures titled net revenue, adjusted operating income or similar measures, such non-GAAP financial measures may be calculated
differently from how we calculate our non-GAAP financial measures, which reduces their overall usefulness as comparative measures. Because of these limitations, you should consider net revenue and adjusted operating income alongside other financial
performance measures, including total revenue, operating income and our other financial results presented in accordance with U.S. GAAP.
The following table sets forth a reconciliation of operating income to adjusted operating income:
Three Months Ended
March 31,
|
Six Months Ended
March 31,
|
|||||||||||||||
(in thousands)
|
2019
|
2018
|
2019
|
2018
|
||||||||||||
Operating income
|
$
|
442
|
$
|
(141
|
)
|
$
|
1,332
|
$
|
157
|
|||||||
Amortization of intangible assets (1)
|
236
|
201
|
444
|
394
|
||||||||||||
Stock-based compensation (2)
|
107
|
245
|
236
|
416
|
||||||||||||
Amortization of acquired inventory valuation (3)
|
67
|
-
|
129
|
-
|
||||||||||||
Adjusted operating income
|
$
|
852
|
$
|
305
|
$
|
2,141
|
$
|
967
|
(1) |
Amortization of intangible assets represents non-cash amortization expense or impairment expense, if any, attributable to acquisition-related intangible assets, including any portion that is allocated to
noncontrolling interests. Management believes that making this adjustment aids in comparing the Company’s operating results with other companies in our industry that have not engaged in acquisitions.
|
(2) |
The Company eliminates the impact of stock-based compensation because it does not consider such non-cash expenses to be indicative of the Company’s core operating performance. The exclusion of stock-based compensation expenses also
facilitates comparisons of the Company’s underlying operating performance on a period-to-period basis.
|
(3) |
The Company has excluded the impact of amortization of acquired inventory valuation in connection with acquisitions as such adjustments represent non-cash items, are not consistent in amount and frequency and
are significantly impacted by the timing and size of the Company’s acquisitions.
|
Results of Operations – Segment Financial Results – Three and Six Months Ended March 31, 2019 and 2018
The following table sets forth our segment financial results:
Three Months Ended
March 31,
|
Six Months Ended
March 31,
|
|||||||||||||||
(in thousands)
|
2019
|
2018
|
2019
|
2018
|
||||||||||||
Revenue:
|
||||||||||||||||
Global Logistics Services
|
$
|
16,865
|
$
|
13,695
|
$
|
35,670
|
$
|
26,550
|
||||||||
Manufacturing
|
2,452
|
2,094
|
4,533
|
4,019
|
||||||||||||
Life Sciences
|
1,652
|
81
|
3,093
|
81
|
||||||||||||
Total Revenues
|
20,969
|
15,870
|
43,296
|
30,650
|
||||||||||||
Gross Profit:
|
||||||||||||||||
Global Logistics Services
|
3,908
|
3,526
|
8,295
|
6,919
|
||||||||||||
Manufacturing
|
1,375
|
1,274
|
2,523
|
2,471
|
||||||||||||
Life Sciences
|
1,087
|
41
|
2,039
|
41
|
||||||||||||
Total gross profit
|
6,370
|
4,841
|
12,857
|
9,431
|
||||||||||||
Income from Operations:
|
||||||||||||||||
Global Logistics Services
|
440
|
499
|
1,467
|
1,135
|
||||||||||||
Manufacturing
|
616
|
377
|
1,056
|
803
|
||||||||||||
Life Sciences
|
363
|
10
|
608
|
10
|
||||||||||||
Total income from operations by segment
|
1,419
|
886
|
3,131
|
1,948
|
||||||||||||
Corporate administrative expense
|
(741
|
)
|
(826
|
)
|
(1,355
|
)
|
(1,397
|
)
|
||||||||
Amortization expense
|
(236
|
)
|
(201
|
)
|
(444
|
)
|
(394
|
)
|
||||||||
Interest expense
|
(198
|
)
|
(117
|
)
|
(360
|
)
|
(234
|
)
|
||||||||
Net income before taxes
|
244
|
(258
|
)
|
972
|
(77
|
)
|
||||||||||
Income taxes
|
(69
|
)
|
41
|
(253
|
)
|
40
|
||||||||||
Net income
|
$
|
175
|
$
|
(217
|
)
|
$
|
719
|
$
|
(37
|
)
|
Results of Operations – Janel Corporation – Three Months Ended March 31, 2019 and 2018
The following table sets forth our corporate group expenses:
Three Months Ended
March 31,
|
||||||||
(in thousands)
|
2019
|
2018
|
||||||
Corporate expenses
|
$
|
582
|
$
|
470
|
||||
Amortization of intangible assets
|
236
|
201
|
||||||
Stock-based compensation
|
142
|
245
|
||||||
Merger and acquisition expenses
|
17
|
111
|
||||||
Total corporate expenses
|
$
|
977
|
$
|
1,027
|
Expenses
Corporate expenses, which include amortization of intangible assets, stock-based compensation and merger and acquisition expenses, decreased by $50 to $977, or 4.9% in the three months ended March 31,
2019 as compared to $1,027 for the three months ended March 31, 2018. The decrease was due primarily to higher accounting related professional expenses in prior year, and lower stock-based compensation expense and lower merger related expenses for
the quarter.
Amortization of Intangible Assets
For the three months ended March 31, 2019 and 2018, corporate amortization expenses were $236 and $201, respectively, an increase of $35, or 17.4%. The increase was primarily related to the acquisitions
of Aves, Antibodies, Honor and Sea Cargo.
Interest Expense
Interest expense for the consolidated Company increased $81, or 69.2%, to $198 for the three months ended March 31, 2019 from $117 for the three months ended March 31, 2018. The increase was due
primarily to our new senior secured term loan facility and subordinated promissory notes in connection with the Antibodies and Honor acquisitions, partially off-set by a lower debt level at the manufacturing segment.
Income Taxes
On a consolidated basis, the Company recorded an income tax benefit of ($69) for the three months ended March 31, 2019, as compared to an income tax expense of $41 for the three months ended March 31,
2018. The increase was due to the new tax rate change and related one-time income tax benefit of $49. On December 22, 2017, the United States enacted tax reform legislation through the Tax Cuts and Jobs Act, which significantly changes the existing
U.S. tax laws, including a reduction in the corporate tax rate from 34% to 21%. As a result of enactment of the legislation, the Company made a reasonable estimate and recorded an additional one-time income tax benefit of $49 during the first quarter
of fiscal 2018, related to the estimated re-measurement of certain deferred tax assets, primarily net operating losses and deferred tax liabilities attributable to intangible assets. In 2016, a deferred tax asset was established to reflect a net
operating loss carryforward, which the Company has begun using, and is expected to continue to use, through ongoing profitability.
Preferred Stock Dividends
Preferred stock dividends include the Company's Series A Convertible Preferred Stock (the “Series A Stock”) and dividends accrued but not paid on the Company's Series C Cumulative Preferred Stock (the
"Series C Stock"). For the three months ended March 31, 2019 and 2018, preferred stock dividends were $148 and $91, respectively. The increase of $57, or 62.64%, was the result of a higher number of shares of Series C Stock outstanding to support
acquisitions and the increase in dividend rate as of January 1, 2019 to 6%. The shares of Series A Stock were repurchased by the Company on September 24, 2018 and retired on September 27, 2018. See note 8 to the consolidated financial statements for
additional information.
Net Income
Net income was $175, or $0.18 per diluted share, for the three months ended March 31, 2019 compared to a loss of ($217), or ($0.38) per diluted share, for the three months ended March 31, 2018. The
increase was primarily due to the increase in operating profits from each of our segments and the inclusion of our new Life Science segment, off-set by higher income tax expense.
Income Available to Common Stockholders
Income available to holders of common shares ("Common Stockholders") was $27, or $0.03 per diluted share, for the three months ended March 31, 2019 compared to a loss of ($308), or ($.54) per diluted
share, for the three months ended March 31, 2018. The decrease primarily was due to the amendment on October 17, 2017 to the annual dividend rate, as discussed in note 8 to the consolidated financial statements, which was treated as a gain on
extinguishment for accounting purposes. The fair value prior to and after modification was $8,224 and $6,912, respectively, for a change of $1,312. In accordance with ASC 260 Earnings Per Share, this incremental benefit is treated as an adjustment to
earning per share for Common Stockholders.
Results of Operations - Global Logistics Services – Three Months Ended March 31, 2019 and 2018
Our Global Logistics Services business helps its clients move and manage freight efficiently to reduce inventories and to increase supply chain speed and reliability. Key services include customs entry
filing, arrangement of freight forwarding by air, ocean and ground, warehousing, cargo insurance procurement, logistics planning, product repackaging and online shipment tracking.
Global Logistics Services – Selected Financial Information:
Three Months Ended
March 31,
|
||||||||
(in thousands)
|
2019
|
2018
|
||||||
Revenue
|
$
|
16,865
|
$
|
13,695
|
||||
Forwarding expense
|
12,957
|
10,169
|
||||||
Net Revenue
|
$
|
3,908
|
$
|
3,526
|
||||
Gross profit margin
|
23
|
%
|
26
|
%
|
||||
Income from Operations
|
$
|
440
|
$
|
499
|
Revenue
Total revenue for the three months ended March 31, 2019 was $16,865, as compared to $13,695 for the three months ended March 31, 2018, an increase of $3,170 or 23.2%. The increase in revenue was largely
due to the inclusion of the acquisitions of Honor and Sea Cargo as compared to the prior year period and higher transportation prices. Organic growth was approximately flat compared to the prior year period.
Forwarding Expenses
Forwarding expenses for the three months ended March 31, 2019 increased by $2,788, or 27.4%, to $12,957 as compared to $10,169 for the three months ended March 31, 2018. Forwarding expenses as a
percentage of revenue were 76.8% and 74.3% for the three months ended March 31, 2019 and March 31, 2018, respectively. Similar to the revenue increase, the increase in forwarding expenses primarily was due to acquisitions and higher purchased
transportation expenses.
Net Revenue
Net revenue for the three months ended March 31, 2019 was $3,908, an increase of $382, or 10.8%, as compared to $3,526 for the three months ended March 31, 2018. This increase was mainly the result of additional net
revenue from the acquisitions discussed above, which were not included in the prior year, and approximately flat organic growth for the quarter in our base of business. Net revenue as a percentage of gross revenue declined to 23.2% versus
25.7% the prior year due to the mix of business and higher freight rates.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three months ended March 31, 2019 were $3,468, as compared to $3,027 for the three months ended March 31, 2018. This increase of $441, or 14.6%, was
largely attributed to the additional expenses from businesses acquired versus the prior year period. As a percentage of net revenue, selling, general and administrative expenses were 20.6% and 22.1% of revenue for the three months ended March 31,
2019 and 2018, respectively.
Income from Operations
Income from operations before income taxes increased to $440 for the three months ended March 31, 2019, as compared to $499 for the three months ended March 31, 2018, a decrease of $59, or 11.8%. Income
from operations grew slower than net revenue due to acquisitions and a smaller investment in growth initiatives. Our operating margin as a percentage of net revenue for the three months ended March 31, 2019 was 11.3%, versus 14.2% in the prior year
period.
Results of Operations - Manufacturing – Three Months Ended March 31, 2019 and 2018
The Company's manufacturing segment includes its majority-owned Indco subsidiary, which manufactures and distributes industrial
mixing equipment.
Manufacturing – Selected Financial Information:
Three Months Ended
March 31,
|
||||||||
(in thousands)
|
2019
|
2018
|
||||||
Revenue
|
$
|
2,452
|
$
|
2,094
|
||||
Gross profit
|
$
|
1,375
|
$
|
1,274
|
||||
Gross profit margin
|
56
|
%
|
61
|
%
|
||||
Income from Operations
|
$
|
616
|
$
|
377
|
Revenue
Total revenue was $2,452 and $2,094 for the three months ended March 31, 2019 and 2018, respectively, an increase of 17.1%. The revenue growth reflected strong growth across the business.
Cost of Sales
Cost of sales was $1,077 and $820 for the three months ended March 31, 2019 and 2018, respectively, an increase of $257 or 31.3% due to increased sales.
Gross Profit and Margin
Gross profit was $1,375 and $1,274 for the three months ended March 31, 2019 and 2018, respectively. Gross profit margin for the three months ended March 31, 2019 declined to 56.1%, compared to 60.8%
for the three months ended March 31, 2018, due to product mix shift to some lower margin products.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $759 and $897 for the three months ended March 31, 2019 and 2018, respectively, a decrease of $138 or 15.4%. Selling, general and administrative
expenses at Indco decreased as a percentage of revenue due to a product mix shift.
Income from Operations
Income from operations of $616 for the three months ended March 31, 2019 increased 63.4% compared to $377 for the three months ended March 31, 2019.
Results of Operations – Life Sciences – Three Months Ended March 31, 2019 and 2018
The Company's Life Sciences segment comprises two life science businesses we acquired through the acquisitions of Aves and Antibodies, both of which manufacture high-quality antibodies and other immunoreagents for
biomedical research.
Life Sciences – Selected Financial Information:
Three Months Ended
March 31,
|
||||||||
(in thousands)
|
2019
|
2018
|
||||||
Revenue
|
$
|
1,652
|
$
|
81
|
||||
Gross profit
|
$
|
1,087
|
$
|
41
|
||||
Gross profit margin
|
66
|
%
|
51
|
%
|
||||
Income from Operations
|
$
|
363
|
$
|
10
|
The Life Sciences segment began to be reported as a segment beginning with the three-month period ended December 31, 2018. Aves was acquired on March 5, 2018, and Antibodies was acquired on June 22, 2018.
Revenue
Total revenue was $1,652 and $81 for the three months ended March 31, 2019 and 2018, respectively.
Cost of Sales
Cost of sales was $565 and $40 for the three months ended March 31, 2019 and 2018, respectively.
Gross Profit and Margin
Gross profit was $1,087 and $41 for the three months ended March 31, 2019 and 2018, respectively. Gross profit and margins increased due to acquisitions. In the three months ended
March 31, 2019, the Life Sciences segment had gross profit margins of 65.8%.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $724 and $31 for the three months ended March 31, 2019 and 2018, respectively.
Income from Operations
Income from operations for the three months ended March 31, 2019 and 2018 was $363 and $10, or 22% and 12%, respectively of segment revenue.
Results of Operations – Janel Corporation – Six Months Ended March 31, 2019 and 2018
The following table sets forth our corporate group expenses:
Six Months Ended
March 31,
|
||||||||
(in thousands)
|
2019
|
2018
|
||||||
Corporate expenses
|
$
|
1,045
|
$
|
856
|
||||
Amortization of intangible assets
|
444
|
394
|
||||||
Stock-based compensation
|
236
|
416
|
||||||
Merger and acquisition expenses
|
74
|
125
|
||||||
Total corporate expenses
|
$
|
1,799
|
$
|
1,791
|
Expenses
Corporate expenses, which include amortization of intangible assets, stock-based compensation and merger and acquisition expenses, increased by $8 to $1,799, or 0.5% in the six months ended March 31,
2019 as compared to $1.791 for the six months ended March 31, 2018.
Amortization of Intangible Assets
For the six months ended March 31, 2019 and 2018, corporate amortization expenses were $444 and $394, respectively, an increase of $50, or 12.7%. The increase was primarily related to the acquisitions
of Aves, Antibodies, Honor and Sea Cargo.
Interest Expense
Interest expense for the consolidated Company increased was $126, or 53.9%, to $360 for the six months ended March 31, 2019 from $234 for the six months ended March 31, 2018. The increase was due
primarily to our new senior secured term loan facility and subordinated promissory notes in connection with the Antibodies and Honor acquisitions, partially off-set by a lower debt level at the manufacturing segment.
Income Taxes
On a consolidated basis, the Company recorded an income tax expense of $253 for the six months ended March 31, 2019, as compared to an income tax benefit of $40 for the six months ended March 31, 2018.
The increase was due to the new tax rate change and related one-time income tax benefit of $49. On December 22, 2017, the United States enacted tax reform legislation through the Tax Cuts and Jobs Act, which significantly changes the existing U.S.
tax laws, including a reduction in the corporate tax rate from 34% to 21%.
As a result of enactment of the legislation, the Company made a reasonable estimate and recorded an additional one-time income tax benefit of $49 during the first quarter of fiscal 2018, related to the
estimated re-measurement of certain deferred tax assets, primarily net operating losses and deferred tax liabilities attributable to intangible assets. In 2016, a deferred tax asset was established to reflect a net operating loss carryforward, which
the Company has begun using, and is expected to continue to use, through ongoing profitability.
Preferred Stock Dividends
Preferred stock dividends include the Company's Series A Stock and dividends accrued but not paid on the Company's Series C Stock. For the six months ended March 31, 2019 and 2018, preferred stock
dividends were $270 and $197, respectively. The increase of $73, or 37.1%, was the result of a higher number of shares of Series C Stock outstanding to support acquisitions and increase in dividend rate as of January 1, 2019 to 6%. The shares of
Series A Stock were repurchased by the Company on September 24, 2018 and retired on September 27, 2018. See note 8 to the consolidated financial statements for additional information.
Net Income
Net income was $719, or $0.77 per diluted share, for the six months ended March 31, 2019 compared to a loss of ($37), or ($0.06) per diluted share, for the six months ended March 31, 2018. The increase
was primarily due to the increase in operating profits from each of our segments and the inclusion of our new Life Science segment, off-set by higher income tax expense.
Income Available to Common Stockholders
Income available to Common Stockholders was $449, or $0.48 per diluted share, for the six months ended March 31, 2019 compared to $1,078, or $1.91 per diluted share, for the six months ended March 31,
2018. The decrease primarily was due to the amendment on October 17, 2017 to the annual dividend rate, as discussed in note 8 to the consolidated financial statements, which was treated as a gain on extinguishment for accounting purposes. The fair
value prior to and after modification was $8,224 and $6,912, respectively, for a change of $1,312. In accordance with ASC 260 Earnings Per Share, this incremental benefit is treated as an adjustment to earnings per share for Common Stockholders.
Results of Operations - Global Logistics Services – Six Months Ended March 31, 2019 and 2018
Our Global Logistics Services business helps its clients move and manage freight efficiently to reduce inventories and to increase supply chain speed and reliability. Key services include customs entry
filing, arrangement of freight forwarding by air, ocean and ground, warehousing, cargo insurance procurement, logistics planning, product repackaging and online shipment tracking.
Global Logistics Services – Selected Financial Information:
Six Months Ended
March 31,
|
||||||||
(in thousands)
|
2019
|
2018
|
||||||
Revenue
|
$
|
35,670
|
$
|
26,550
|
||||
Forwarding expense
|
27,375
|
19,631
|
||||||
Net Revenue
|
$
|
8,295
|
$
|
6,919
|
||||
Gross profit margin
|
23
|
%
|
26
|
%
|
||||
Income from Operations
|
$
|
1,467
|
$
|
1,135
|
Revenue
Total revenue for the six months ended March 31, 2019 was $35,670, as compared to $26,550 for the three months ended March 31, 2018, an increase of $9,120 or 34.4%. The increase in revenue was largely
due to the inclusion of the acquisitions of Honor and Sea Cargo as compared to the prior year period and higher transportation prices. The business also experienced strong organic growth largely benefiting from customers moving freight prior to new
proposed governmental trade policies.
Forwarding Expenses
Forwarding expenses for the six months ended March 31, 2019 increased by $7,744, or 39.5%, to $27,375 as compared to $19,631 for the six months ended March 31, 2018. Forwarding expenses as a percentage
of revenue were 76.8% and 74.0% for the six months ended March 31, 2019 and March 31, 2018, respectively. Similar to the revenue increase, the increase in forwarding expenses primarily was due to acquisitions, higher purchased transportation expenses
and an increase in our base of business.
Net Revenue
Net revenue for the six months ended March 31, 2019 was $8,295, an increase of $1,376 or 19.9%, as compared to $6,919 for the six months ended March 31, 2018. This increase was mainly the result of additional net
revenue from the acquisitions discussed above, which were not included in the prior year, and strong organic growth for the quarter in our base of business as customers moved freight prior to new proposed governmental trade policies. Net revenue
as a percentage of gross revenue declined to 23.3% versus 26.1% the prior year due to the mix of business and higher freight rates.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the six months ended March 31, 2019 were $6,828, as compared to $5,784 for the six months ended March 31, 2018. This increase of $1,044, or 18.1%, was
largely attributed to the additional expenses from businesses acquired versus the prior year period. As a percentage of revenue, selling, general and administrative expenses were 19.1% and 20.2% of revenue for the three months ended March 31, 2019
and 2018, respectively.
Income from Operations
Income from operations before income taxes increased to $1,467 for the six months ended March 31, 2019, as compared to $1,135 for the six months ended March 31, 2018, an increase of $332, or 29.3%.
Income from operations grew faster than net revenue due to acquisitions and a smaller investment in growth initiatives. Our operating margin as a percentage of net revenue for the six months ended March 31, 2019 was 17.7%, versus 16.4% in the prior
year period.
Results of Operations - Manufacturing – Six Months Ended March 31, 2019 and 2018
The Company's manufacturing segment includes its majority-owned Indco subsidiary, which manufactures and distributes industrial
mixing equipment.
Manufacturing – Selected Financial Information:
Six Months Ended
March 31,
|
||||||||
(in thousands)
|
2019
|
2018
|
||||||
Revenue
|
$
|
4,533
|
$
|
4,019
|
||||
Gross profit
|
$
|
2,523
|
$
|
2,471
|
||||
Gross profit margin
|
56
|
%
|
61
|
%
|
||||
Income from Operations
|
$
|
1,056
|
$
|
803
|
Revenue
Total revenue was $4,533 and $4,019 for the six months ended March 31, 2019 and 2018, respectively, an increase of 12.8%. The revenue growth reflected strong growth across the business.
Cost of Sales
Cost of sales for the six months ended March 31, 2019 and 2018 was $2,010 and $1,548, respectively, an increase of $462 or 29.8% due to increased sales.
Gross Profit and Margin
Gross profit was $2,523 and $2,471 for the six months ended March 31, 2019 and 2018, respectively. Gross profit margin for the six months ended March 31, 2019 decreased to 55.7%, compared to 61.3% for
the six months ended March 31, 2018 due to product mix shifting to some lower margin products.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $1,467 and $1,698 for the six months ended March 31, 2019 and 2018, respectively, a decrease of $201 or 12.1%. Selling, general and administrative
expenses at Indco decreased as a percentage of revenue due to a product mix shift.
Income from Operations
Income from operations of $848 for the six months ended March 31, 2019 increased 5.6% compared to $803 for the six months ended March 31, 2019.
Results of Operations – Life Sciences – Six Months Ended March 31, 2019 and 2018
The Company's Life Sciences segment comprises two life science businesses that we acquired through the acquisitions of Aves and Antibodies, both of which manufacture high-quality antibodies and other immunoreagents for
biomedical research.
Life Sciences – Selected Financial Information:
Six Months Ended
March 31,
|
||||||||
(in thousands)
|
2019
|
2018
|
||||||
Revenue
|
$
|
3,093
|
$
|
81
|
||||
Gross profit
|
$
|
2,039
|
$
|
41
|
||||
Gross profit margin
|
66
|
%
|
51
|
%
|
||||
Income from Operations
|
$
|
608
|
$
|
10
|
The Life Sciences segment began to be reported as a segment beginning with the three-month period ended December 31, 2018. Aves was acquired on March 5, 2018, and Antibodies was
acquired on June 22, 2018.
Revenue
Total revenue was $3,093 and $81 for the six months ended March 31, 2019 and 2018, respectively.
Cost of Sales
Cost of sales was $1,054 and $40 for the six months ended March 31, 2019 and 2018, respectively.
Gross Profit and Margin
Gross profit was $2,039 and $41 for the six months ended March 31, 2019 and 2018, respectively. Gross profit and margins increased due to acquisitions. In the six months ended
March 31, 2019, the life sciences segment had gross profit margins of 65.9%.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $1,431 and $31 for the six months ended March 31, 2019 and 2018, respectively.
Income from Operations
Income from operations for the six months ended March 31, 2019 and 2018 was $608 and $10, or 19.7% and 12%, respectively of segment revenue.
LIQUIDITY AND CAPITAL RESOURCES
General
Our ability to satisfy liquidity requirements, including satisfying debt obligations and fund working capital, day-to-day operating expenses and capital expenditures, depends upon future performance,
which is subject to general economic conditions, competition and other factors, some of which are beyond Janel's control. Subsidiaries depend on commercial credit facilities to fund day-to-day operations as there is a difference between the timing of
collection cycles and the timing of payments to vendors. Generally, Janel does not make significant capital expenditures.
As a customs broker, we make significant cash advances for a select group of our credit-worthy customers. These cash advances are for customer obligations such as the payment of duties and taxes to customs authorities
primarily in the U.S. Increases in duty rates could result in increases in the amounts we advance on behalf of our customers. Cash advances are a “pass through” and are not recorded as a component of revenue and expense.
The billings of such advances to customers are accounted for as a direct increase in accounts receivable from the customer and a corresponding increase in accounts payable to governmental customs authorities. These “pass
through” billings can influence our traditional credit collection metrics. For customers that meet certain criteria, we have agreed to extend payment terms beyond our customary terms. Management believes that it has established effective credit
control procedures, and has historically experienced relatively insignificant collection problems.
As of March 31, 2019, the Company's cash and working capital deficiency (current assets minus current liabilities) were $1,381 and $7,494, respectively, as compared to $585 and $6,587 as of September
30, 2018. The increase is considered nominal, representing relatively stable collections from customers and payments of vendors.
Janel's cash flow performance for the three months ended March 31, 2019 is not necessarily indicative of future cash flow performance.
Cash flows from operating activities
Net cash provided by operating activities for the six months ended March 31, 2019 and 2018 was $1,272 and $1,204, respectively. The increase in cash provided by operations for the six months ended March
31, 2019 was driven principally by cash collections from customers.
Cash flows from investing activities
Net cash used in investing activities totaled $2,188 for the six months ended March 31, 2019, versus $2,359 for the prior year period. During the six months ended March 31, 2019, the Company used $1,935
for two acquisitions net of cash acquired. The Company also used $253 for the acquisition of property and equipment for the six months ended March 31, 2019 versus $38 for the six months ended March 31, 2018.
Cash flows from financing activities
Net cash proceeds from financing activities was $1,712 for the six months ended March 31, 2019, versus $913 provided by financing activities for the six months ended March 31, 2018. Net cash proceeds
from financing activities for the six months ended March 31, 2019 primarily included funds from our line of credit debt. Net cash used in financing activities for the six months ended March 31, 2018 period primarily included debt repayment and seller
debt repayments.
Off-Balance Sheet Arrangements
As of March 31, 2019, we had no off-balance sheet arrangements or obligations.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Critical accounting estimates are those that we believe are both significant and require us to make difficult, subjective, or complex judgments, often because we need to estimate the effect of inherently uncertain matters.
These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstance. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that
require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended September 30, 2018 in the Critical Accounting Policies and
Estimates section of Management's Discussion and Analysis of Financial Condition and Results of Operations included in Item 7 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2018.
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized
and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required
disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of
March 31, 2019, the end of the period covered by this Quarterly Report on Form 10-Q.
Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, because a material weaknesses in the Company’s internal control over financial reporting existed at September 30, 2018 and had not
been remediated by the end of the period covered by this Quarterly Report on Form 10-Q, the Company’s disclosure controls and procedures were not effective as of the end of the period covered by this Quarterly Report on Form 10-Q. These material
weaknesses in the Company’s internal control over financial reporting and the Company’s remediation efforts are described below.
Material Weaknesses in Internal Control Over Financial Reporting
The Company’s management, including our Chief Executive Officer and Chief Financial Officer, have identified material weaknesses in the Company’s internal control over financial reporting. A material weakness is a deficiency, or a combination of
deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
In connection with the preparation of the Company's Annual Report on Form 10-K, management identified the following material weaknesses as of September 30, 2018:
• |
We did not maintain adequate controls over journal entry approval;
|
• |
We did not maintain adequate controls over inventory valuation as it relates to overhead costs.
|
Based on this assessment and the material weaknesses described above, management concluded that the Company’s internal control over financial reporting was not effective as of September 30, 2018 and had not been remediated by the end of the period
covered by this Quarterly Report on Form 10-Q.
Our management performed analyses, substantive procedures and other post-closing activities with the assistance of consultants and other professional advisors in order to ensure the validity,
completeness and accuracy of our income tax provision and accounting for complex and/or non-routine transactions and the related disclosures. Accordingly, our management believes that the financial statements included in this Form 10-Q as of March
31, 2019 are fairly presented, in all material respects, and in conformity with U.S. GAAP.
Remediation Plan
We have developed and are executing on our plan to remediate our material weaknesses in connection with the information technology controls by expanding our in-house expertise on information technology
general controls, as well as continuing to consult with external third parties. This process commenced during the fourth quarter of fiscal 2018 and is ongoing.
Our management believes that the foregoing efforts will effectively remediate the material weaknesses. That said, the new and enhanced controls have not operated for a sufficient amount of time to
conclude that the material weaknesses have been remediated. As we continue to evaluate and work to improve our internal control over financial reporting, our management may decide to take additional measures to address the material weaknesses or
modify the remediation plan described above.
Internal control over financial reporting, no matter how well designed, has inherent limitations. Therefore, even those controls determined to be effective may not prevent or detect misstatements and
can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of
changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our executive management team, together with our board of directors, is committed to achieving and maintaining a strong control environment, high ethical standards, and financial reporting integrity.
Changes in Internal Control over Financial Reporting
As disclosed above under “Remediation Plan,” there were changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report
on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In addition, as discussed above, during the quarter ended December 31, 2018, the Company implemented changes to
its accounting policies, practices and internal controls over financial reporting in connection with its adoption of ASC Topic 606.
PART II - OTHER INFORMATION
Janel is occasionally subject to claims and lawsuits which typically arise in the normal course of business. While the outcome of these claims cannot be predicted with certainty, management does not
believe that the outcome of any of these legal matters will have a material adverse effect on the Company’s business, results of operations, financial condition or cash flows.
In December 2017, Janel Group received a Notice of Copyright Infringement letter from counsel for Warren Communications News, Inc. (“Warren”), the publisher of the International Trade Today (“ITT”) newsletter. The
letter alleges that Janel Group infringed upon Warren’s registered copyrights in its ITT newsletter. The Company believes it has meritorious defenses to the allegations. The Company is not presently able to reasonably estimate potential losses, if
any, related to the allegations.
For a discussion of the Company’s potential risks or uncertainties, please see “Part I—Item 1A—Risk Factors” in our annual report on Form 10-K for the fiscal year ended September 30, 2018 filed with the SEC. There have been no material changes to
the risk factors disclosed in our annual report on Form 10-K for the fiscal year ended September 30, 2018.
There were no unregistered sales of equity securities during the three months ended March 31, 2019. In addition, there were no shares of common stock purchased by us during the three months ended March 31, 2019.
Exhibit No.
|
||
Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer (filed herewith)
|
||
Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer (filed herewith)
|
||
Section 1350 Certification of Principal Executive Officer (filed herewith) | ||
Section 1350 Certification of Principal Financial Officer (filed herewith)
|
||
101
|
Interactive data files providing financial information from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 for the three months ended March 31, 2019 and 2018 in XBRL (Extensible
Business Reporting Language) pursuant to Rule 405 of Regulation S-T: (i) Consolidated Balance Sheets as of March 31, 2019 and September 30, 2018, (ii) Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018,
(iii) Consolidated Statement of Changes in Stockholders' Equity for the three months ended March 31, 2019 and 2018, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018, and (v) Notes to Consolidated
Financial Statements*
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: November 22, 2019
|
JANEL CORPORATION
|
Registrant
|
|
/s/ Dominique Schulte
|
|
Dominique Schulte
|
|
Chairman, President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
Dated: November 22, 2019
|
JANEL CORPORATION
|
Registrant
|
|
/s/ Vincent A. Verde
|
|
Vincent A. Verde
|
|
Principal Financial Officer, Treasurer and Secretary
|
41